<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:c9e057a1-0ac0-4679-ac34-0702807569e2"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="9931d83f-44ea-4a83-96e9-55ff8f8fad68"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-10T23:30:05Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:6a934682-70ba-4243-96f2-c00eed63b7c4"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<contained>
                                <Binary>
                                	<id value="image0"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image001.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image001.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image0"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image1"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image002.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image002.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image1"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image2"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image003.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image003.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image2"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image3"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image004.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image004.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image3"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image4"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image005.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image005.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image4"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image5"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image006.jpg"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image006.jpg"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image5"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image6"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image007.jpg"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image007.jpg"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image6"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image7"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image008.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image008.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image7"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image8"/>
                                	<!-- example format -->
                                	<contentType value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image009.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image009.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image8"/>
                        		</valueReference>
               </extension>
              
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:center;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:normal;
	text-decoration:underline;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:normal;
	font-style:italic;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:0in;
	margin-right:17.85pt;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:0in;
	margin-right:17.65pt;
	margin-bottom:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\, Car17\, Char Char Char\, Char Char1\,Annotationtext\,Char\,Char Char Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1\,Comment Text Char1 Char Char\,Comment Text Char2 Ch";
	mso-style-link:"Comment Text Char2\, Car17 Char1\, Char Char Char Char1\, Char Char1 Char1\,Annotationtext Char1\,Char Char Char Char1\,Char Char2\,Comment Text Char Char Char Char Char\,Comment Text Char Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:black;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial Bold",serif;
	color:black;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:black;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:black;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char1";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:black;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:1.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;
	color:black;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.CommentTextChar2
	{mso-style-name:"Comment Text Char2\, Car17 Char1\, Char Char Char Char1\, Char Char1 Char1\,Annotationtext Char1\,Char Char Char Char1\,Char Char2\,Comment Text Char Char Char Char Char\,Comment Text Char Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char1";
	mso-style-link:"Comment Text\, Car17\, Char Char Char\, Char Char1\,Annotationtext\,Char\,Char Char Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1\,Comment Text Char1 Char Char\,Comment Text Char2 Ch";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.default0, li.default0, div.default0
	{mso-style-name:default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.default1, li.default1, div.default1
	{mso-style-name:default1;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.paragraph0, li.paragraph0, div.paragraph0
	{mso-style-name:paragraph0;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.ReferenceText, li.ReferenceText, div.ReferenceText
	{mso-style-name:"Reference Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:1.15in;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	color:windowtext;
	font-weight:bold;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;}
p.ReferenceHeading2, li.ReferenceHeading2, div.ReferenceHeading2
	{mso-style-name:"Reference Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:42.5pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-42.5pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.ReferenceHeading3, li.ReferenceHeading3, div.ReferenceHeading3
	{mso-style-name:"Reference Heading 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.ListEnd, li.ListEnd, div.ListEnd
	{mso-style-name:"List End";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.Instructions
	{mso-style-name:Instructions;
	color:teal;
	display:none;
	font-style:italic;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	mso-style-link:"Table Footnote Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.TableFootnoteChar
	{mso-style-name:"Table Footnote Char";
	mso-style-link:"Table Footnote";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.CharChar1
	{mso-style-name:"Char Char1";
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Lijstalinea1, li.Lijstalinea1, div.Lijstalinea1
	{mso-style-name:Lijstalinea1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpFirst, li.Lijstalinea1CxSpFirst, div.Lijstalinea1CxSpFirst
	{mso-style-name:Lijstalinea1CxSpFirst;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpMiddle, li.Lijstalinea1CxSpMiddle, div.Lijstalinea1CxSpMiddle
	{mso-style-name:Lijstalinea1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Lijstalinea1CxSpLast, li.Lijstalinea1CxSpLast, div.Lijstalinea1CxSpLast
	{mso-style-name:Lijstalinea1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:28.35pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:center;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar1
	{mso-style-name:"Endnote Text Char1";
	mso-style-link:"Endnote Text";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table\:Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\, Car17 Char\, Char Char Char Char\, Char Char1 Char\,Annotationtext Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char Char\,Comment Text Char2 Char Char";
	font-family:"Times New Roman",serif;}
p.SOPheading, li.SOPheading, div.SOPheading
	{mso-style-name:"SOP heading";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-indent:-.5in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;
	text-decoration:underline;}
p.TableFootnoteLetter, li.TableFootnoteLetter, div.TableFootnoteLetter
	{mso-style-name:"Table Footnote Letter";
	mso-style-link:"Table Footnote Letter Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.TableFootnoteLetterChar
	{mso-style-name:"Table Footnote Letter Char";
	mso-style-link:"Table Footnote Letter";
	font-family:"Times New Roman",serif;}
p.TableParagraph, li.TableParagraph, div.TableParagraph
	{mso-style-name:"Table Paragraph";
	margin:0in;
	text-align:center;
	line-height:11.35pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	font-family:Courier;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:gray;
	background:#E6E6E6;}
p.CM1, li.CM1, div.CM1
	{mso-style-name:CM1;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EUAlbertina",serif;
	color:windowtext;}
p.CM3, li.CM3, div.CM3
	{mso-style-name:CM3;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EUAlbertina",serif;
	color:windowtext;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:green'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext"><img alt="Description: Description: Description: BT_1000x858px" height="18" id="Picture 1" src="#image0" width="21"/>This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS 50 mg powder for concentrate for solution for infusion.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Each vial contains 50 mg of brentuximab vedotin. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">After reconstitution (see section 6.6), each mL contains 5 mg of brentuximab vedotin.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS is an antibody‑drug conjugate composed of a CD30‑directed monoclonal antibody (recombinant chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE).</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Excipient with known effect"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Each vial contains approximately 13.2 mg of sodium. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL form"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB">Powder for concentrate for solution for infusion.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB">White to off‑white cake or powder. </span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       Clinical particulars"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><a name="OLE_LINK2"></a><a name="OLE_LINK5"></a></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Hodgkin lymphoma</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).</span></p><p class="MsoPlainText"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following </span><span style="font-size:11.0pt">autologous stem cell transplant</span><span lang="EN-GB" style="font-size:11.0pt"> (ASCT) (see section 5.1).</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family: "Times New Roman",serif'>ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): </span></p><p class="MsoPlainText" style="margin-left:66.55pt;text-indent:-.25in"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>following ASCT, or</span></p><p class="MsoPlainText" style="margin-left:66.55pt;text-indent:-.25in"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>2.</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.</span></p><p class="MsoNormal"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Systemic anaplastic large cell lymphoma</span></u></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) (see section 5.1).</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory sALCL.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Cutaneous T‑cell lymphoma </span></u></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T‑cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).</span></p><p class="Paragraph" style="margin-bottom:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">ADCETRIS should be administered under the supervision of a physician experienced in the use of anti‑cancer agents.</span></p><p class="MsoNormal" style="text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><b><u><span lang="EN-GB"></span></u></b></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Previously Untreated HL</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose in combination with chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]) is 1.2 mg/kg administered as an intravenous infusion over 30 minutes on days 1 and 15 of each 28‑day cycle for 6 cycles (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Primary prophylaxis with growth factor support (G-CSF), beginning with the first dose, is recommended for all patients with previously untreated HL receiving combination therapy (see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Refer to the summary of product characteristics (SmPC) of chemotherapy agents given in combination with ADCETRIS for patients with previously untreated HL. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">HL at increased risk of relapse or progression </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS treatment should start following recovery from ASCT based on clinical judgment. These patients should receive up to 16 cycles (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Relapsed or refractory HL</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The recommended starting dose for the retreatment of patients who have previously responded to treatment with ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. Alternatively, treatment may be started at the last tolerated dose (see section 5.1).</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal"><a name="OLE_LINK6"></a><a name="OLE_LINK7"><span lang="EN-GB">Treatment should be continued until disease progression or unacceptable toxicity<sup> </sup>(see section 4.4).</span></a></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients who achieve stable disease or better should receive a minimum of 8 cycles and </span><span lang="EN-GB">up to a maximum of 16 cycles (approximately 1 year) (see section 5.1). </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Previously untreated sALCL</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose in combination with chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP]) is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks for 6 to 8 cycles </span><span lang="EN-GB">(see section 5.1). </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Primary prophylaxis with G-CSF, beginning with the first dose, is recommended for all patients </span><span lang="EN-GB">with previously untreated sALCL receiving combination therapy (see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Refer to the SmPCs of chemotherapy agents given in combination with ADCETRIS for patients with previously untreated sALCL. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Relapsed or refractory sALCL</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The recommended starting dose for the retreatment of patients who have previously responded to treatment with ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. Alternatively, treatment may be started at the last tolerated dose (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Treatment should be continued until disease progression or unacceptable toxicity<sup> </sup>(see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients who achieve stable disease or better should receive a minimum of 8 cycles and up to a maximum of 16 cycles (approximately 1 year) (see section 5.1). </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">CTCL</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients with CTCL should receive up to 16 cycles (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">General</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">If the patient’s weight is more than 100 kg, the dose calculation should use 100 kg (see section 6.6).</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Complete blood counts should be monitored prior to administration of each dose of this treatment (see section 4.4). </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Patients should be monitored during and after infusion (see section 4.4). </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Dose adjustments</span></u></p><p class="Default" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Neutropenia</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">If neutropenia develops during treatment it should be managed by dose delays. See Table 1 and Table 2 for appropriate dosing recommendations for monotherapy and combination therapy, respectively (see also section 4.4). </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 1: Dosing recommendations for neutropenia with monotherapy<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none" width="99%"> <tr> <td style="width:37.12%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="37%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><a name="_Hlk8891520"><b><span lang="EN-GB">Severity grade of   neutropenia</span></b></a></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(signs and symptoms </span></b><span lang="EN-GB">[abbreviated   description of CTCAE<sup>a</sup>])</span></p> </td> <td style="width:62.88%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="62%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Modification of dosing schedule</span></b></p> </td> </tr> <tr> <td style="width:37.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="37%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="SV">Grade 1   (&lt; LLN‑1500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="SV">                 &lt; LLN‑1.5 x 10<sup>9</sup>/L) or</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Grade 2   (&lt; 1500‑1000/mm<sup>3</sup></span></p> <p class="MsoNormal" style="page-break-after:avoid"><sup></sup><span lang="EN-GB">&lt; 1.5‑1.0 x 10<sup>9</sup>/L)</span></p> </td> <td style="width:62.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="62%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Continue   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style="width:37.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="37%"> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="EN-GB">Grade 3 (&lt; 1,000‑500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="EN-GB">                  &lt; 1.0‑0.5 x 10<sup>9</sup>/L) or</span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="EN-GB">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><sup></sup><span lang="EN-GB">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style="width:62.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="62%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Withhold   dose until toxicity returns to ≤ Grade 2 or baseline then   resume treatment at the same dose and schedule<sup>b</sup>. Consider G‑CSF   or GM‑CSF in subsequent cycles for patients who develop Grade 3 or   Grade 4 neutropenia.</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0; see Neutrophils/granulocytes; LLN = lower limit of normal.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:17.85pt;text-indent:-17.85pt"><sup><span lang="EN-GB" style="font-size:11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Patients who develop Grade 3 or Grade 4 lymphopenia may continue treatment without interruption.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><b><span lang="EN-GB">Table 2: Dosing recommendations for neutropenia during combination therapy </span></b></p><p class="MsoNormal"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:98.84%;margin-left:5.4pt;border-collapse:collapse;border:none" width="98%"> <tr> <td style="width:36.54%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="36%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Severity grade of neutropenia</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(signs and symptoms </span></b><span lang="EN-GB">[abbreviated   description of CTCAE<sup>a</sup>])</span></p> </td> <td style="width:63.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="63%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Modification of dosing schedule</span></b></p> </td> </tr> <tr style="height:101.7pt"> <td style="width:36.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:101.7pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="SV">Grade 1   (&lt; LLN‑1500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="SV">                 &lt; LLN‑1.5 x 10<sup>9</sup>/L) or</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="SV">Grade 2   (&lt; 1500‑1000/mm<sup>3</sup></span></p> <p class="MsoNormal" style="page-break-after:avoid"><sup></sup><span lang="SV">&lt; 1.5‑1.0 x 10<sup>9</sup>/L)</span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="SV">Grade 3 (&lt; 1,000‑500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="EN-GB">&lt; 1.0‑0.5 x 10<sup>9</sup>/L) or</span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><span lang="EN-GB">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class="MsoNormal" style="margin-left:41.3pt;text-indent:-41.3pt;page-break-after:   avoid"><sup></sup><span lang="EN-GB">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style="width:63.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:101.7pt" valign="top" width="63%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Primary   prophylaxis with G-CSF, beginning with the first dose, is recommended for all   patients receiving combination therapy. </span><span lang="EN-GB">Continue with   the same dose and schedule.</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see Neutrophils/granulocytes; LLN = lower limit of normal.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Peripheral neuropathy</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">If peripheral sensory or motor neuropathy emerges or worsens during treatment see Table 3 and 4 for appropriate dosing recommendations for monotherapy and combination therapy, respectively (see section 4.4).</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Table 3: Dosing recommendations for new or worsening peripheral sensory or motor neuropathy with monotherapy</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none" width="99%"> <tr> <td style="width:43.98%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="43%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Severity of peripheral sensory or motor neuropathy   </span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(signs and symptoms </span></b><span lang="EN-GB">[abbreviated   description of CTCAE<sup>a</sup>])</span></p> </td> <td style="width:56.02%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="56%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Modification of dose and schedule</span></b></p> </td> </tr> <tr> <td style="width:43.98%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="43%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 1 (paraesthesia and/or loss of reflexes,   with no loss of function)</span></p> </td> <td style="width:56.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="56%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Continue   with the same dose and schedule. </span></p> </td> </tr> <tr> <td style="width:43.98%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="43%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 2 (interfering with function but not with   activities of daily living) </span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td style="width:56.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="56%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Withhold   dose until toxicity returns to ≤ Grade 1 or baseline,   then restart treatment at a reduced dose of 1.2 mg/kg </span><span lang="EN-GB">up to a maximum of 120 mg</span><span lang="EN-GB"> every   3 weeks.</span></p> </td> </tr> <tr> <td style="width:43.98%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="43%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 3 (interfering with activities of daily   living)</span></p> </td> <td style="width:56.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="56%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Withhold   dose until toxicity returns to ≤ Grade 1 or baseline, then   restart treatment at a reduced dose of 1.2 mg/kg </span><span lang="EN-GB">up to a maximum of 120 mg</span><span lang="EN-GB"> every   3 weeks.</span></p> </td> </tr> <tr> <td style="width:43.98%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="43%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 4 (sensory neuropathy that is disabling or   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style="width:56.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="56%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Discontinue   treatment.</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0; see neuropathy: motor; neuropathy: sensory; and neuropathic pain. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Table 4: Dosing recommendations for new or worsening peripheral sensory or motor neuropathy during combination therapy</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:102.58%;margin-left:5.4pt;border-collapse:collapse;border:none" width="102%"> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:28.74%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Combination therapy with AVD</span></b></p> </td> <td style="width:28.74%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Combination therapy with CHP</span></b></p> </td> </tr> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Severity of peripheral sensory or motor neuropathy   </span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(signs and symptoms </span></b><span lang="EN-GB">[abbreviated   description of CTCAE<sup>a</sup>])</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Modification of dose and schedule </span></b></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Modification of dose and schedule </span></b></p> </td> </tr> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 1 (paraesthesia and/or loss of reflexes,   with no loss of function)</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Continue   with the same dose and schedule.</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Continue   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p class="MsoNormal" style="margin-left:41.1pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 2 (interfering with function but not with   activities of daily living)</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Reduce   dose to 0.9 mg/kg up </span><span lang="EN-GB">to a maximum of 90 mg</span><span lang="EN-GB"> every 2 weeks.</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="margin-bottom:3.0pt"><u><span lang="EN-GB">Sensory   neuropathy</span></u><span lang="EN-GB">: Continue treatment at same dose level.</span></p> <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Motor   neuropathy</span></u><span lang="EN-GB">: Reduce dose to 1.2 mg/kg, up to   a maximum of 120 mg every 3 weeks.</span></p> </td> </tr> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 3 (interfering with activities of daily   living)</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Withhold   treatment with ADCETRIS until toxicity is ≤ Grade 2, then   restart treatment at a reduced dose to 0.9 mg/kg up </span><span lang="EN-GB">to a maximum of 90 mg</span><span lang="EN-GB">every 2 weeks.</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="margin-bottom:3.0pt"><u><span lang="EN-GB">Sensory   neuropathy</span></u><span lang="EN-GB">: Reduce dose to 1.2 mg/kg up to a   maximum of 120 mg every 3 weeks.</span></p> <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Motor   neuropathy</span></u><span lang="EN-GB">: Discontinue treatment.</span></p> </td> </tr> <tr> <td style="width:42.54%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="42%"> <p class="MsoNormal" style="margin-left:39.7pt;text-indent:-39.7pt;page-break-after:   avoid"><span lang="EN-GB">Grade 4 (sensory neuropathy which is disabling or   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Discontinue   treatment.</span></p> </td> <td style="width:28.74%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="28%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Discontinue   treatment.</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:4.5pt"><sup><span lang="EN-GB" style="font-size:9.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt"> Grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see neuropathy: motor; neuropathy: sensory; and neuropathic pain. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Special patient populations</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Renal and hepatic impairment</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Combination therapy</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Patients with renal impairment should be closely monitored for adverse events. </span><span lang="EN-GB">There is no clinical trial experience using ADCETRIS in combination with chemotherapy in patients with renal impairment, where serum creatinine is ≥ 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance is ≤ 40 mL/minute. Use of ADCETRIS in combination with chemotherapy should be avoided in patients with severe renal impairment. </span></p><h5 align="left" style="text-align:left;page-break-after:auto"></h5><p class="MsoNormal"><span lang="EN-GB">Patients with hepatic impairment should be closely monitored for adverse events. The recommended starting dose in patients with mild hepatic impairment receiving ADCETRIS in combination with AVD is 0.9 mg/kg administered as an intravenous infusion over 30 minutes every 2 weeks. The recommended starting dose in patients with mild hepatic impairment receiving ADCETRIS in combination with CHP is 1.2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. There is no clinical trial experience using ADCETRIS in combination with chemotherapy in patients with hepatic impairment, where total bilirubin is &gt; 1.5 times the upper limit of normal (ULN) (unless due to Gilbert syndrome), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are &gt; 3 times the ULN, or &gt; 5 times the ULN if their elevation may be reasonably ascribed to the presence of HL in the liver. Use of ADCETRIS in combination with chemotherapy should be avoided in patients with moderate and severe hepatic impairment.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Monotherapy</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB">The recommended starting dose in patients with severe renal impairment is 1.2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. Patients with renal impairment should be closely monitored for adverse events (see section 5.2).</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The recommended starting dose in patients with hepatic impairment is 1.2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. Patients with hepatic impairment should be closely monitored for adverse events (see section 5.2).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Elderly</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">The dosing recommendations for patients aged 65 and older are the same as for adults.</span><span style="color:windowtext"> Currently available data are described in sections 4.8, 5.1 and 5.2.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The safety and efficacy of</span><span lang="EN-GB"> ADCETRIS in</span><span lang="EN-GB"> children less than 18 years have not yet been established. </span>Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In nonclinical studies, thymus depletion has been observed (see section 5.3).</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><b></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="default0" style="page-break-after:avoid"></p><p class="default0"><span lang="EN-GB" style="font-size:11.0pt">The recommended dose of ADCETRIS is infused over 30 minutes. </span></p><p class="default0"></p><p class="default0"><span lang="EN-GB" style="font-size:11.0pt">For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</span></p><p class="MsoNormal"><b><u><span lang="EN-GB"></span></u></b></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS must not be administered as an intravenous push or bolus. ADCETRIS should be administered through a dedicated intravenous line and it must not be mixed with other medicinal products (see section 6.2).</span></p><p class="default0"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Combined use of bleomycin and ADCETRIS causes pulmonary toxicity (see section 4.5). </span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Progressive multifocal leukoencephalopathy</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal"><span lang="EN-GB">John Cunningham virus (JCV) reactivation resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in ADCETRIS‑treated patients. PML has been reported in patients who received this treatment after receiving multiple prior chemotherapy regimens. PML is a rare demyelinating disease of the central nervous system that results from reactivation of latent JCV and is often fatal. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients should be closely monitored for new or worsening neurological, cognitive, or behavioural signs or symptoms, which may be suggestive of PML. ADCETRIS should be held for any suspected case of PML. Suggested evaluation of PML includes neurology consultation, gadolinium‑enhanced magnetic resonance imaging of the brain and cerebrospinal fluid analysis for JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A negative JCV PCR does not exclude PML. Additional follow up and evaluation may be warranted if no alternative diagnosis can be established. ADCETRIS dosing should be permanently discontinued if a diagnosis of PML is confirmed.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The physician should be particularly alert to symptoms suggestive of PML that the patient may not notice (e.g., cognitive, neurological, or psychiatric symptoms).</span></p><p class="MsoNormal"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:0in;page-break-after: avoid;text-autospace:none"><u><span lang="EN-GB">Pancreatitis</span></u></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:0in;page-break-after: avoid;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:0in;text-autospace:none"><span lang="EN-GB">Acute pancreatitis has been observed in patients treated with ADCETRIS. Fatal outcomes have been reported.</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:0in;text-autospace:none"></p><p class="MsoListParagraphCxSpLast" style="margin-left:0in;text-autospace:none"><span lang="EN-GB">Patients should be closely monitored for new or worsening abdominal pain, which may be suggestive of acute pancreatitis. Patient evaluation may include physical examination, laboratory evaluation for serum amylase and serum lipase, and abdominal imaging, such as ultrasound and other appropriate diagnostic measures. ADCETRIS should be held for any suspected case of acute pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute pancreatitis is confirmed. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Pulmonary toxicity</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Cases of pulmonary toxicity</span><span lang="EN-GB">, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes,</span><span lang="EN-GB"> have </span><span lang="EN-GB">been </span><span lang="EN-GB">reported </span><span lang="EN-GB">in patients </span><span lang="EN-GB">receiving ADCETRIS. Although a causal association </span><span lang="EN-GB">with ADCETRIS</span><span lang="EN-GB"> has not been established, the risk of pulmonary toxicity cannot be ruled out. In the event of new or worsening pulmonary symptoms (e.g. cough, dyspnoea), a prompt diagnostic evaluation should be performed and patients should be treated appropriately.</span><span lang="EN-GB">Consider holding ADCETRIS dosing during evaluation and until symptomatic improvement.</span></p><p class="MsoListParagraph" style="margin-left:0in;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Serious infections and opportunistic infections</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Serious infections such as pneumonia, staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with ADCETRIS. Patients should be carefully monitored during treatment for the emergence of possible serious and opportunistic infections.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Infusion‑related reactions</span></u></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Immediate and delayed infusion‑related reactions (IRR), as well as anaphylactic reactions, have been reported. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt;color:black">Patients should be carefully monitored during and after infusion.</span><span lang="EN-GB" style="font-size:11.0pt"> <span style="color:black">If an anaphylactic reaction occurs, administration of ADCETRIS should be immediately and permanently discontinued and appropriate medical therapy should be administered.</span></span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">If an IRR occurs, the infusion should be interrupted and appropriate medical management instituted. The infusion may be restarted at a slower rate after symptom resolution. Patients who have experienced a prior IRR should be premedicated for subsequent infusions. Premedication may include paracetamol, an antihistamine and a corticosteroid. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">IRRs are more frequent and more severe in patients with antibodies to brentuximab vedotin (see section 4.8).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Tumour lysis syndrome</span></u></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in;page-break-after: avoid"></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"><span lang="EN-GB" style="font-size:11.0pt">Tumour lysis syndrome (TLS) has been reported with ADCETRIS. Patients with rapidly proliferating tumour and high tumour burden are at risk of tumour lysis syndrome. These patients should be monitored closely and managed according to best medical practice. Management of TLS may include aggressive hydration, monitoring of renal function, correction of electrolyte abnormalities, anti‑hyperuricaemic therapy, and supportive care.</span></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Peripheral neuropathy</span></u></p><p class="Default" style="page-break-after:avoid"></p><p class="Default"><a name="_Hlk519675029"><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS may cause peripheral neuropathy, both sensory and motor. ADCETRIS‑induced peripheral neuropathy is typically an effect of cumulative exposure to this medicinal product and is reversible in most cases. In clinical trials, the majority of patients had resolution or improvement of their symptoms (see section 4.8). Patients should be monitored for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning sensation, neuropathic pain or weakness. Patients experiencing new or worsening peripheral neuropathy may require a delay and a dose </span></a><span lang="EN-GB" style="font-size:11.0pt">reduction of ADCETRIS or discontinuation of treatment (see section 4.2). </span></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Haematological toxicities</span></u></p><p class="Default" style="page-break-after:avoid"></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">Grade 3 or Grade 4 anaemia, thrombocytopenia, and prolonged (≥ 1 week) Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete blood counts should be monitored prior to administration of each dose. If Grade 3 or Grade 4 neutropenia develops, refer to section 4.2.</span></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Febrile neutropenia</span></u></p><p class="Default" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection with an absolute neutrophil count &lt; 1.0 x 10<sup>9</sup>/L, fever ≥ 38.5 <sup>0</sup>C; ref CTCAE v3) has been reported with treatment with ADCETRIS. Complete blood counts should be monitored prior to administration of each dose of treatment. Patients should be monitored closely for fever and managed according to best medical practice if febrile neutropenia develops.</span></p><p class="Default"></p><p class="Default"><span style="font-size:11.0pt">In combination therapy with AVD or CHP, advanced age was a risk factor for febrile neutropenia. </span><span lang="EN-GB" style="font-size:11.0pt">When ADCETRIS is administered in combination with AVD or CHP, primary prophylaxis with G‑CSF, beginning with the first dose, is recommended for all patients regardless of age.</span></p><p class="ListEnd"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Stevens‑Johnson syndrome and toxic epidermal necrolysis</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"><span lang="EN-GB" style="font-size:11.0pt">Stevens‑Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. Fatal outcomes have been reported. If SJS or TEN occur, ADCETRIS should be discontinued and appropriate medical therapy should be administered.</span></p><p class="MsoNormal"></p><p class="ListEnd" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt;color:black">Gastrointestinal complications</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in;page-break-after: avoid"><span lang="EN-GB" style="font-size:11.0pt">Gastrointestinal (GI) complications including intestinal obstruction, ileus, enterocolitis, neutropenic colitis, erosion, ulcer, perforation and haemorrhage, some with fatal outcomes, have been reported in patients treated with ADCETRIS. In the event of new or worsening GI symptoms, perform a prompt diagnostic evaluation and treat appropriately.</span></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in;page-break-after: avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatotoxicity</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB" style="color:windowtext">Hepatotoxicity in the form of elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) has been reported with ADCETRIS. </span><span lang="EN-GB" style="color:windowtext">Serious cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre‑existing liver disease, comorbidities, and concomitant medications may also increase the risk. </span><span lang="EN-GB" style="color:windowtext">Liver function </span><span lang="EN-GB" style="color:windowtext">should be </span><span lang="EN-GB" style="color:windowtext">tested before initiating the treatment and </span><span lang="EN-GB" style="color:windowtext">routinely</span><span lang="EN-GB" style="color:windowtext"> monitored in patients receiving ADCETRIS. </span><span lang="EN-GB" style="color:windowtext">Patients experiencing hepatotoxicity may require a delay, change in dose or discontinuation of ADCETRIS.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Hyperglycaemia</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Hyperglycaemia has been reported during clinical trials in patients with an elevated Body Mass Index (BMI) with or without a history of diabetes mellitus. However, any patient who experiences an event of hyperglycaemia should have their serum glucose closely monitored. Anti‑diabetic treatment should be administered as appropriate. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and hepatic impairment</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">There is limited experience in patients with renal and hepatic impairment. Available data indicate that MMAE clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations (see section 5.2). </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">CD30+ CTCL</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The size of the treatment effect in CD30 + CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level evidence. In two single arm phase II studies of ADCETRIS, disease activity has been shown in the subtypes Sézary syndrome (SS), lymphomatoid papulosis (LyP) and mixed CTCL histology. These data suggest that efficacy and safety can be extrapolated to other CTCL CD30+ subtypes. Nevertheless, ADCETRIS should be used with caution in other CD30+ CTCL patients after careful consideration of the potential benefit‑risk on an individual basis (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Sodium content in excipients</span></u></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in;page-break-after: avoid"></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"><span lang="EN-GB" style="font-size:11.0pt">This medicinal product contains 13.2 mg sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult. </span></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Traceability"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal"><span lang="EN-GB">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Interaction with medicinal products metabolised through CYP3A4 route (CYP3A4 inhibitors/inducers)</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Co‑administration of brentuximab vedotin with ketoconazole, a strong CYP3A4 and P‑gp inhibitor, increased the exposure to the antimicrotubule agent MMAE by approximately 73%, and did not alter the plasma exposure to brentuximab vedotin. Therefore, co‑administration of brentuximab vedotin with strong CYP3A4 and P‑gp inhibitors may increase the incidence of neutropenia. If neutropenia develops, refer to </span><span lang="EN-GB">Tables 1 and 2 for dosing recommendations for neutropenia (see section 4.2). </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Co‑administration of </span><span lang="EN-GB">brentuximab vedotin</span><span lang="EN-GB"> with rifampicin, a strong CYP3A4 inducer, did not alter the plasma exposure to </span><span lang="EN-GB">brentuximab vedotin</span><span lang="EN-GB">. Though PK data are limited, co-administration of rifampicin appeared to reduce plasma concentrations of MMAE metabolites that could be assayed. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Co</span><span lang="EN-GB">‑</span><span lang="EN-GB">administration of midazolam, a CYP3A4 substrate, with brentuximab vedotin did not alter the metabolism of midazolam; therefore brentuximab vedotin is not expected to alter the exposure to medicines that are metabolised by CYP3A4 enzymes.</span></p><p class="MsoNormal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Doxorubicin, vinblastine and dacarbazine (AVD) </span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">The serum and plasma pharmacokinetic characteristics of </span><span lang="EN-GB">antibody drug conjugate (</span><span lang="EN-GB">ADC) and MMAE respectively following administration of brentuximab vedotin in combination with AVD were similar to that in monotherapy.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Co‑administration of brentuximab vedotin did not affect the plasma exposure of AVD.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:windowtext">Cyclophosphamide, Doxorubicin and Prednisone (CHP)</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">The serum and plasma pharmacokinetic characteristics of ADC and MMAE, respectively, following administration of brentuximab vedotin in combination with CHP were similar to that in monotherapy.</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Co‑administration of brentuximab vedotin is not expected to affect the exposure of CHP.</span></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:windowtext"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:windowtext">Bleomycin</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">There were no formal drug‑drug interaction studies with brentuximab vedotin and bleomycin (B). In a phase 1 dose finding and safety study (SGN35‑009), unacceptable pulmonary toxicity (including 2 fatal events) was noted in 11 of 25 patients (44%) treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal events were reported with brentuximab vedotin + AVD. Therefore, co‑administration of ADCETRIS with bleomycin is contraindicated (see section 4.3).</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Women of childbearing potential </span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Women of childbearing potential should be using two methods of effective contraception during treatment with ADCETRIS and until 6 months after treatment. </span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">There are no data from the use of ADCETRIS in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS should not be used during pregnancy unless the benefit to the mother outweighs the potential risks to the foetus. If a pregnant woman needs to be treated she should be clearly advised on the potential risk to the foetus.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">See the fertility section below pertaining to advice for women whose male partners are being treated with ADCETRIS.</span></p><p class="Paragraph" style="margin-bottom:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast‑feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">There are no data as to whether brentuximab vedotin or its metabolites are excreted in human milk. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">A risk to the newborn/infant cannot be excluded. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">A decision should be made whether to discontinue breast‑feeding or to discontinue/abstain from this therapy, taking into account a potential risk of breast‑feeding for the child and the benefit of therapy for the woman.</span></p><p class="MsoNormal" style="text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">In non‑clinical studies, </span><span lang="EN-GB">brentuximab vedotin</span><span lang="EN-GB"> treatment has resulted in testicular toxicity, and may alter male fertility. MMAE has been shown to have aneugenic properties (see section 5.3). Therefore, men being treated with this medicine are advised to have sperm samples frozen and stored before treatment. Men being treated with this medicine are advised not to father a child during treatment and for up to 6 months following the last dose. </span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">ADCETRIS may have a moderate influence on the ability to drive and use machines (e.g. dizziness), see section 4.8. </span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Summary of the safety profile</span></u></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The safety profile of ADCETRIS is based on available clinical trial data, the Named Patient Program (NPP), and post‑marketing experience to date. Frequencies of adverse reactions described below and in Table 5 have been determined based on data generated from clinical studies. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><i><span lang="EN-GB">Monotherapy</span></i></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">In the pooled dataset of </span><span lang="EN-GB" style="color:windowtext">ADCETRIS</span><span lang="EN-GB" style="color:windowtext"> as monotherapy across HL, sALCL and CTCL studies (SG035‑0003, SG035‑0004, SGN35‑005, SGN35‑006, C25001 and C</span><span lang="EN-GB" style="color:windowtext">25007, see section 5.1)</span><span lang="EN-GB" style="color:windowtext"> the most frequent adverse reactions (≥ 10%) were infections,</span><span lang="EN-GB" style="color:windowtext"> peripheral sensory neuropathy, nausea</span><span lang="EN-GB" style="color:windowtext">, fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash, cough, vomiting, arthralgia, peripheral motor neuropathy</span><span lang="EN-GB" style="color:windowtext">, infusion-related reactions, pruritus, constipation, dyspnoea, weight decreased, myalgia and abdominal pain.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Serious adverse drug reactions occurred in 12% of patients. The frequency of unique serious adverse drug reactions was ≤ 1%.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Adverse events led to treatment discontinuation in 24% of patients receiving ADCETRIS. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">The safety data in patients retreated with ADCETRIS (SGN35‑006, see section 5.1) were consistent with those observed in the combined pivotal phase 2 studies, with the exception of peripheral motor neuropathy, which had a higher incidence (28% vs. 9% in the pivotal phase 2 studies) and was primarily Grade 2. Patients also had a higher incidence of arthralgia, Grade 3 anaemia, and back pain compared to patients observed in the combined pivotal phase 2 studies.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">T</span><span lang="EN-GB">he safety data in patients with relapsed or refractory HL who had not received an autologous stem cell transplant and were treated with the recommended dose of 1.8 mg/kg every three weeks in a single‑arm phase 4 study (n = 60), the phase 1 dose escalation and clinical pharmacology studies (n = 15 patients) and in the NPP (n = 26 patients) (see section 5.1) were consistent with the safety profile of the pivotal clinical studies. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Combination therapy </span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">For safety information of chemotherapy agents given in combination with ADCETRIS (doxorubicin, vinblastine and dacarbazine (AVD) or cyclophosphamide, doxorubicin and prednisone (CHP)), refer to their summary of product characteristics. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In the studies of ADCETRIS as combination therapy in 662 patients with previously untreated advanced HL (C25003) and 223 patients with previously untreated CD30+ </span>peripheral T-cell lymphoma (<span lang="EN-GB">PTCL) (SGN35‑014), the most common adverse reactions (≥ 10%) were: infections, neutropenia, peripheral sensory neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia, alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia, myalgia, back pain, peripheral motor neuropathy, upper respiratory tract infection, and dizziness. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In patients receiving ADCETRIS combination therapy, serious adverse reactions occurred in 34% of patients. Serious adverse reactions occurring in ≥ 3% of patients included febrile neutropenia (15%), pyrexia (5%), and neutropenia (3%). </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adverse events led to treatment discontinuation in 10% of patients. Adverse events that led to treatment discontinuation in ≥ 2% of patients included peripheral sensory neuropathy, and peripheral neuropathy.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Adverse reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred Term (see Table 5). Within each System Organ Class, adverse reactions are listed under frequency categories of: Very common (≥ 1/10); Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥ 1/10,000 to &lt; 1/1,000); Very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). </span><span lang="EN-GB">Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 5: Adverse reactions to ADCETRIS <br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:493.5pt;border-collapse:collapse;border:none" width="658"> <thead> <tr style="page-break-inside:avoid;height:15.1pt"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="149"> <p class="MsoNormal" style="text-autospace:none"><a name="_Hlk5943718"><b><span lang="EN-GB">System organ class</span></b></a></p> </td> <td style="width:212.6pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="283"> <p class="MsoNormal"><b><span lang="EN-GB">Adverse reactions (monotherapy)</span></b></p> </td> <td style="width:169.15pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="226"> <p class="MsoNormal"><b><span lang="EN-GB">Adverse reactions <br/>    (combination therapy)</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Infections    and infestations</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common: </span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Infection</span><sup><span lang="EN-GB">a</span></sup><span lang="EN-GB">, upper respiratory tract    infection</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Infection</span><sup><span lang="EN-GB">a</span></sup><span lang="EN-GB">, upper respiratory tract infection</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="PT">Herpes    zoster, pneumonia, herpes simplex, oral candidiasis</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Pneumonia, oral candidiasis,    sepsis/septic shock, herpes zoster</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Pneumocystis    jiroveci pneumonia, staphylococcal bacteraemia, cytomegalovirus infection or    reactivation,</span><span lang="EN-GB"> sepsis/septic shock</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Herpes simplex, Pneumocystis jiroveci    pneumonia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Frequency not known:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Progressive multifocal    leukoencephalopathy</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Blood    and lymphatic system disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Neutropenia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Neutropenia<sup>a</sup>, anaemia,    febrile neutropenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Anaemia, thrombocytopenia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Thrombocytopenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Febrile neutropenia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Immune    system disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Anaphylactic reaction</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Anaphylactic transfusion reaction</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism    and nutrition disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Decreased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Hyperglycaemia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Hyperglycaemia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Tumour lysis syndrome</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Tumour lysis syndrome</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="658"> <p class="MsoNormal"><b><span lang="EN-GB">Psychiatric disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Very common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Insomnia</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Nervous    system disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Peripheral sensory neuropathy,    peripheral motor neuropathy</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Peripheral sensory neuropathy<sup>a</sup>,    peripheral motor neuropathy<sup>a</sup>, dizziness</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Dizziness</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Demyelinating polyneuropathy</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Respiratory,    thoracic and mediastinal disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Very common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Cough, dyspnoea</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Cough, dyspnoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Gastrointestinal    disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Nausea, diarrhoea, vomiting, constipation,    abdominal pain</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Nausea, constipation, vomiting,    diarrhoea, abdominal pain, stomatitis</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Pancreatitis acute</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Pancreatitis acute</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Hepatobiliary    disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="283"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Alanine    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="226"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Alanine    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Skin    and subcutaneous tissue disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Rash<sup>a</sup>, pruritus</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Alopecia, rash<sup>a</sup></span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Alopecia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Pruritus</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Uncommon:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Stevens-Johnson syndrome/toxic epidermal    necrolysis</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Stevens-Johnson syndrome<sup>b</sup></span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Musculoskeletal    and connective tissue disorders</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Arthralgia, myalgia</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal"><span lang="EN-GB">Bone pain, arthralgia, myalgia, back    pain</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:14.35pt"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="283"> <p class="MsoNormal"><span lang="EN-GB">Back pain</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="226"> <p class="MsoNormal"></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.1pt"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">General    disorders and administration site conditions</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Very    common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Fatigue,    pyrexia, infusion-related reactions<sup>a</sup></span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Fatigue,    pyrexia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Chills</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Infusion-related    reactions<sup>a</sup>, chills</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:493.5pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="658"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Investigations</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:111.75pt;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="149"> <p class="MsoNormal"><span lang="EN-GB">Very common:</span></p> </td> <td style="width:212.6pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="283"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Weight    decreased</span></p> </td> <td style="width:169.15pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="226"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Weight    decreased</span></p> </td> </tr> </thead> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Represents pooling of preferred terms.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Toxic epidermal necrolysis was not reported in the combination therapy setting.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Description of selected adverse reactions</span></u></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><i><span lang="EN-GB" style="font-size:11.0pt">Neutropenia and febrile neutropenia</span></i></p><p class="Paragraph" style="margin-bottom:0in;text-indent:28.35pt;page-break-after: avoid"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Monotherapy</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">In clinical trials, neutropenia</span><span lang="EN-GB" style="font-size:11.0pt"> led to dose delays in 14% of patients. Grade 3 neutropenia was reported in </span><span lang="EN-GB" style="font-size:11.0pt">13% and Grade 4 neutropenia was reported in 5% of patients. No patients required dose reduction or discontinued treatment for neutropenia. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal"><span lang="EN-GB">Severe and prolonged (≥ 1 week) neutropenia can occur with this treatment which may increase the risk of patients developing serious infections. Febrile neutropenia reported in &lt; 1% of the patients (see section 4.2).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">In the pivotal phase 2 population </span><span lang="EN-GB" style="color:windowtext">(SG035‑0003 and SG035‑0004)</span><span lang="EN-GB" style="color:windowtext">, </span><span lang="EN-GB" style="color:windowtext">the median duration of Grade 3 or Grade 4 neutropenia was limited (1 week); 2% of patients had Grade 4 neutropenia that lasted ≥ 7 days. Less </span><span lang="EN-GB" style="color:windowtext">than half of the patients in the pivotal phase 2 population with Grade 3 or Grade 4 neutropenia had temporally associated infections, and the majority of temporally associated infections were Grade 1 or Grade 2.</span></p><p class="MsoNormal"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt;color:black">Combination therapy</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">In the clinical trials of </span><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> as combination therapy, neutropenia led to dose delays in 19% of patients. Grade 3 neutropenia was reported in 17% and Grade 4 neutropenia was reported in 41% of patients. Two percent of patients required dose reduction and &lt; 1% discontinued one of more of the study drugs due to neutropenia. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Febrile neutropenia was reported in 20% of the patients who did not receive primary prophylaxis with G-CSF (see section 4.2). The frequency of febrile neutropenia was 13% in patients who received primary prophylaxis with G-CSF. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Serious infections and opportunistic infections</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Monotherapy</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">In clinical trials, serious infections </span><span lang="EN-GB">and opportunistic infections occurred in 10% of patients, sepsis or septic shock occurred in &lt; 1% of the patients. The most commonly reported opportunistic infections were herpes zoster and herpes simplex.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB">Combination therapy</span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB">In the clinical trials of </span><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> as combination therapy, </span><span lang="EN-GB">serious infections including opportunistic infections occurred in 15% of patients; sepsis, neutropenic sepsis, septic shock or bacteraemia occurred in 4% of the patients. The most commonly reported opportunistic infections were herpes viral infections.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><i><span lang="EN-GB" style="font-size:11.0pt">Peripheral neuropathy</span></i></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Monotherapy </span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span style="font-size:11.0pt">In clinical trials treatment emergent neuropathy occurred </span><span lang="EN-GB" style="font-size:11.0pt">in 59% of the population, peripheral motor neuropathy occurred in 14% of patients. </span><span style="font-size:11.0pt">Peripheral neuropathy led to treatment discontinuation in 15%, dose reductions in 15%, and </span><span lang="EN-GB" style="font-size:11.0pt">dose delays in 17% of patients. </span><span style="font-size:11.0pt">For patients who experienced peripheral neuropathy the median time of onset of peripheral neuropathy was 12 weeks. The median duration of treatment for patients who discontinued due to peripheral neuropathy was 12 cycles.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Among patients who experienced peripheral neuropathy in the pivotal phase 2 studies (SG035-0003 and SG035‑0004) and randomised phase 3 monotherapy studies (SGN35‑005 and C25001), the median follow up time from end of treatment until last evaluation ranged from 48.9 to 98 weeks. At the time of last evaluation, most of the patients (82-85%) who experienced peripheral neuropathy had resolution or improvement of their peripheral neuropathy symptoms. The median time from onset to resolution or improvement for all events ranged from 16 to 23.4 weeks. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In patients with relapsed or refractory HL or sALCL who were retreated with ADCETRIS (SGN35‑006), the majority of patients (80%) also had improvement or resolution of their peripheral neuropathy symptoms at the time of last evaluation.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><a name="_Hlk519675104"><span lang="EN-GB">Combination therapy</span></a></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">In the clinical trial of ADCETRIS as combination therapy with AVD, </span><span lang="EN-GB" style="color:windowtext">treatment emergent neuropathy occurred in 67% of the population; peripheral motor neuropathy occurred in 11% of patients. Peripheral neuropathy led to treatment discontinuation in 7%, dose reductions in 21%, and dose delays in 1% of patients. For patients who experienced peripheral neuropathy the median time of onset of peripheral neuropathy was 8 weeks. Patients who discontinued due to peripheral neuropathy received a median of 8 doses of ADCETRIS+AVD (A+AVD) before discontinuation of one or more agents. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until last evaluation was approximately 91 weeks. At the time of last evaluation, most of the patients (76%) who experienced peripheral neuropathy had resolution or improvement of their peripheral neuropathy symptoms. The median time from onset to resolution or improvement of peripheral neuropathy events was 10 weeks (ranged from 0 weeks to 139 weeks).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In the clinical trial of ADCETRIS as combination therapy with CHP, </span><span lang="EN-GB" style="color:windowtext">treatment emergent neuropathy occurred in 52% of the population; peripheral motor neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment discontinuation in 1%, dose reductions in 7% and dose delays in </span><span lang="EN-GB">&lt;</span><span lang="EN-GB" style="color:windowtext">1% of patients. For patients who experienced peripheral neuropathy the median time of onset was 9.1 weeks. Patients who discontinued due to peripheral neuropathy received a median of 5 doses of ADCETRIS + CHP (A+CHP) before discontinuation of one or more agents.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until last evaluation was approximately 177 weeks. At the time of last evaluation, 64% who experienced peripheral neuropathy had resolution or improvement of their peripheral neuropathy symptoms. The median time from onset to resolution or improvement of peripheral neuropathy events was 19.0 weeks (ranged from 0 weeks to 205 weeks).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Infusion-related reactions</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Monotherapy</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">IRRs, such as headache, rash, back pain, vomiting, chills, nausea, dyspnoea, pruritus and cough were reported in 13% of patients. </span><span lang="EN-GB">Anaphylactic reactions have been reported (see section 4.4). Symptoms of an anaphylactic reaction may include, but are not limited to, urticaria, angioedema, hypotension and bronchospasm. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Combination therapy</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">IRRs, such as headache, rash, back pain, vomiting, chills, nausea, dyspnoea, pruritus, cough, infusion site pain and pyrexia were reported in 8% of patients. Anaphylactic reactions have been reported (see section 4.4). Symptoms of an anaphylactic reaction may include, but are not limited to, urticaria, angioedema, hypotension and bronchospasm.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB">Immunogenicity</span></i></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">In clinical trials, patients were periodically tested for antibodies to brentuximab vedotin using a sensitive electrochemiluminescent immunoassay. There was a higher incidence of </span><span lang="EN-GB">infusion-related reactions observed in</span><span lang="EN-GB"> patients with antibodies </span><span lang="EN-GB">to brentuximab vedotin relative to</span><span lang="EN-GB"> patients </span><span lang="EN-GB">who tested transiently positive or negative.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">The presence of antibodies to brentux</span><span lang="EN-GB">imab vedotin did not correlate with a clinically meaningful reduction in serum brentuximab vedotin levels and did not result in a decrease in the efficacy of brentuximab vedotin. While the presence of antibodies to brentuximab vedotin does not necessarily predict the development of an IRR, there was a higher incidence of IRRs observed in patients with persistently positive anti-drug antibodies (ADA) relative to patients with transiently positive ADA and never positive ADA. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">There was a trend of increased clearance of brentuximab vedotin in paediatric patients confirmed positive for ADAs. No patients aged &lt; 12 years (0 of 11) and 2 patients aged ≥ 12 years (2 of 23) became persistently ADA positive.</span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">Safety was evaluated in a phase 1/2 study in paediatric patients aged 7‑17 years of age (n = 36) with relapsed or refractory (r/r) HL and sALCL (see section 5.1).In this study in 36 patients, no new safety concerns were reported.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><u><span lang="EN-GB">Elderly </span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Monotherapy </span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The safety profile in elderly patients is generally in line with that of adult patients. However, elderly patients may be more susceptible to events such as pneumonia, neutropenia and febrile neutropenia.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Combination therapy </span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">In older patients (≥ 60 years of age; n = 186 [21%]), the incidence of adverse events was similar across treatment arms. More serious adverse events and dose modifications (including dose delays, reductions, and discontinuations) were reported in the older patients compared with the overall study population. Advanced age was a risk factor for febrile neutropenia in patients in both arms. Older patients who received G-CSF primary prophylaxis had lower incidence of neutropenia and febrile neutropenia than those who did not receive G-CSF primary prophylaxis.</span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="background:silver">Appendix V</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">There is no known antidote for overdose of ADCETRIS. In case of overdose, the patient should be closely monitored for adverse reactions, particularly neutropenia, and supportive treatment should be administered (see section 4.4). </span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Pharmacotherapeutic group: Antineoplastic agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC12.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="paragraph0" style="margin-bottom:0in;page-break-after:avoid"></p><p class="paragraph0" style="margin-bottom:0in"><span lang="EN-GB" style="font-size:11.0pt">Brentuximab vedotin</span><span lang="EN-GB" style="font-size:11.0pt"> is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30‑expressing tumour cells. Nonclinical data suggest that the biological activity of </span><span lang="EN-GB" style="font-size:11.0pt">brentuximab vedotin</span><span lang="EN-GB" style="font-size:11.0pt"> results from a multi-step process. Binding of the ADC to CD30 on the cell surface initiates internalisation of the ADC‑CD30 complex, which then traffics to the lysosomal compartment. Within the cell, a single defined active species, MMAE, is released via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, induces cell cycle arrest and results in apoptotic death of the CD30‑expressing tumour cell.</span></p><p class="paragraph0" style="margin-bottom:0in"></p><p class="paragraph0" style="margin-bottom:0in"><span lang="EN-GB" style="font-size:11.0pt">Classical HL, sALCL and subtypes of CTCL (including MF and pcALCL) express CD30 as an antigen on the surface of their malignant cells. This expression is independent of disease stage, line of therapy or transplant status.</span><span lang="EN-GB" style="font-size:11.0pt"> These features make CD30 a target for therapeutic intervention. Because of the CD30‑targeted mechanism of action brentuximab vedotin is able to overcome chemo-resistance as CD30 is consistently expressed in patients who are refractory to multi-agent chemotherapy, irrespective of prior transplant status. </span><span lang="EN-GB" style="font-size:11.0pt">The CD30‑targeted mechanism of action of brentuximab vedotin, the consistent expression of CD30 throughout the classical HL, sALCL and CD30+ CTCL disease and therapeutic spectrums andclinical evidence in CD30‑positive malignancies following multiple lines of treatment provide a biologic rationale for its use in patients with relapsed and refractory classical HL, sALCL with or without prior ASCT and CD30+ CTCL after at least 1 prior systemic therapy.</span></p><p class="paragraph0" style="margin-bottom:0in"></p><p class="paragraph0" style="margin-bottom:0in"><span lang="EN-GB" style="font-size:11.0pt">Contributions to the mechanism of action by other antibody associated functions have not been excluded. </span></p><p class="paragraph0" style="margin-bottom:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Pharmacodynamic effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Cardiac electrophysiology</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Forty‑six (46) patients with CD30‑expressing haematologic malignancies were evaluable of the 52 patients who received 1.8 mg/kg of brentuximab vedotin every 3 weeks as part of a phase 1, single‑arm, open-label, multicenter cardiac safety study. The primary objective was to evaluate the effect of</span><span lang="EN-GB"> brentuximab vedotin on cardiac ventricular re-polarization and the predefined primary analysis was the change in QTc from baseline to multiple time points in Cycle 1.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The upper 90% confidence interval (CI) around the mean effect on QTc was &lt; 10</span><span lang="EN-GB">msec at each of the Cycle 1 and Cycle 3 post-baseline time points. These data indicate the absence of clinically relevant QT prolongation due to brentuximab vedotin administered at a dose of 1.8 mg/kg every 3 weeks in patients with CD30‑expressing malignancies.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB">Hodgkin lymphoma</span></i></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study C25003</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The efficacy and safety of ADCETRIS were evaluated in a randomised, open-label, 2‑arm, multicenter trial in 1334 patients with previously untreated advanced HL in combination with chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]). All patients had a histologically confirmed CD30‑expressing disease. Sixty‑two percent of patients had extranodal site involvement. Of the 1334 patients, 664 patients were randomised to the ADCETRIS + AVD arm and 670 patients were randomised to the ABVD (doxorubicin [A], bleomycin [B], vinblastine [V] and dacarbazine [D]) arm and stratified by number of International Prognostic Factor Project (IPFP) risk factors and region. Patients were treated on days 1 and 15 of each 28‑day cycle with 1.2 mg/kg of ADCETRIS administered as an intravenous infusion over 30 minutes + doxorubicin 25 mg/m<sup>2</sup>, vinblastine 6 mg/m<sup>2</sup>, and dacarbazine 375 mg/m<sup>2</sup>. The median number of cycles received was 6 (range, 1 to 6 cycles). Table 6 provides a summary of the baseline patient and disease characteristics.</span> There were no relevant differences in the patient and disease characteristics between the two arms.</p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 6: Summary of baseline patient and disease characteristics in the phase 3 previously untreated HL study<br/> <br/> </span></b></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:6.45in;border-collapse:collapse" width="619"> <tr style="height:26.4pt"> <td style="width:252.9pt;border-top:windowtext;   border-left:windowtext;border-bottom:black;border-right:white;border-style:   solid;border-width:1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Patient   Characteristics </span></b></p> </td> <td style="width:117.0pt;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="156"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS + AVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 664</span></b></p> </td> <td style="width:94.5pt;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="126"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ABVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 670</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Median age   (range) </span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">35 years   (18‑82)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">37 years   (18‑83)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Patients   ≥ 65 years old n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">60 (9)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">62 (9)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Gender, n   (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">378M (57)</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">286F (43)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">398M (59)</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">272F (41)</span></p> </td> </tr> <tr style="height:13.2pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">ECOG   status, n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="156"></td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="126"></td> </tr> <tr style="height:13.2pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">0 </span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">376 (57)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">378 (57)</span></p> </td> </tr> <tr style="height:13.2pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">1 </span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">260 (39)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">263 (39)</span></p> </td> </tr> <tr style="height:13.2pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28 (4)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">27 (4)</span></p> </td> </tr> <tr style="height:13.2pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Missing</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Disease   Characteristics </span></b></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"></td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"></td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Median   time from HL diagnosis to first dose (range)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">0.92 mo   (0.1‑21.4)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">0.89 mo   (0.0‑81.4)</span></p> </td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Disease   stage<sup>a</sup> at initial diagnosis of HL, n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"></td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"></td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">III</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">237 (36)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">246 (37)</span></p> </td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">IV</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">425 (64)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">421 (63)</span></p> </td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Not applicable</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">1 (&lt; 1)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">1 (&lt; 1)</span></p> </td> </tr> <tr style="height:15.4pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Missing</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2 (&lt; 1 )</span></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Extranodal   involvement at time of diagnosis, n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">411 (62)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">416 (62)</span></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">IPFP<sup>b</sup>   risk factors, n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:9.0pt;page-break-after:avoid"><span lang="EN-GB">0‑1</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">141 (21)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">141 (21)</span></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:9.0pt;page-break-after:avoid"><span lang="EN-GB">2‑3</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">354 (53)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">351 (52)</span></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="margin-left:9.0pt;page-break-after:avoid"><span lang="EN-GB">4‑7</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">169 (25)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">178 (27)</span></p> </td> </tr> <tr style="height:15.85pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Bone   marrow involvement at time of diagnosis or study entry, n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">147(22)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">151 (23)</span></p> </td> </tr> <tr style="height:16.75pt"> <td style="width:252.9pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="337"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">B symptoms<sup>a   </sup>n (%)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="156"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">400 (60)</span></p> </td> <td style="width:94.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="126"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">381 (57)</span></p> </td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">a</span></sup><span lang="EN-GB" style="font-size:9.0pt"> Per Ann Arbor Staging.</span></p><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">b</span></sup><span lang="EN-GB" style="font-size:9.0pt">IPFP = International Prognostic Factor Project.</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The primary endpoint in Study C25003 was modified PFS (mPFS) per independent review facility (IRF), defined as time from randomisation to disease progression, death, or evidence of non-complete response (non-CR) after completion of first-line therapy per IRF followed by subsequent anticancer therapy. Timing of the modified event was the date of the first PET scan post completion of first-line therapy demonstrating the absence of complete response (CR), defined as Deauville score of ≥3. The median modified PFS by IRF assessment was not reached in either treatment arm. The results in the intent-to-treat (ITT) population showed a statistically significant improvement in modified PFS for ADCETRIS+ AVD, with a stratified hazard ratio of 0.770 (95% CI, 0.603; 0.983, p =<sup> </sup>0.035), indicating a 23% reduction in the risk of modified PFS events for ADCETRIS+ AVD versus ABVD. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none">A pre-specified subgroup analysis of mPFS <span lang="EN-GB" style="letter-spacing:-.1pt">by disease stage showed that patients with Stage IV disease had a larger effect compared with the ITT population</span><span lang="EN-GB">,</span><span lang="EN-GB">with an unstratified hazard ratio of 0.71 (95% CI, 0.53; 0.96), compatible with a 29% reduction in the risk of modified PFS events for ADCETRIS+ AVD versus ABVD. Of the ITT population, 846 patients (64%) had Stage IV disease.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">Table 7 provides the efficacy results for modified PFS and overall survival (OS) in the ITT population and patients with Stage IV disease.</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 7: Efficacy results for previously untreated HL patients treated with 1.2 mg/kg of ADCETRIS + AVD on days 1 and 15 of a 28-day cycle (ITT and Stage IV)</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:454.4pt;margin-left:-.15pt;border-collapse:collapse;border:none" width="606"> <tr style="page-break-inside:avoid;height:33.0pt"> <td rowspan="2" style="width:82.85pt;border:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt" width="110"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td colspan="3" style="width:199.15pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 0in 0in 0in;height:33.0pt" width="266"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Intent to Treat (ITT) Population</span></b></p> </td> <td colspan="3" style="width:172.4pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 0in 0in 0in;height:33.0pt" width="230"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Patients with Stage IV Disease</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:33.0pt"> <td style="width:66.8pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b><b><span lang="EN-GB"> + AVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 664</span></b></p> </td> <td style="width:58.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ABVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 670</span></b></p> </td> <td style="width:73.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.0pt" valign="top" width="98"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Stratified Hazard Ratio and p-value</span></b></p> </td> <td style="width:57.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.0pt" valign="top" width="77"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b><b><span lang="EN-GB"> + AVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 425</span></b></p> </td> <td style="width:47.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.0pt" valign="top" width="63"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ABVD</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 421</span></b></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.0pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Unstratified Hazard Ratio and p-value<sup>c</sup></span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:50.05pt"> <td style="width:82.85pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:50.05pt" width="110"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:8.0pt;   margin-left:4.9pt;page-break-after:avoid"><b><span lang="EN-GB">Number of   events (%)</span></b></p> </td> <td style="width:66.8pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;   height:50.05pt" width="89"> <p align="center" class="MsoNormal" style="margin-bottom:8.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">117 (18)</span></p> </td> <td style="width:58.65pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:50.05pt" width="78"> <p align="center" class="MsoNormal" style="margin-bottom:8.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">146 (22)</span></p> </td> <td rowspan="2" style="width:73.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:50.05pt" width="98"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">0.77</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">(95% CI [0.60, 0.98])</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">p-value=</span><span lang="EN-GB" style="color:windowtext">0.035</span></p> </td> <td style="width:57.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:50.05pt" width="77"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">77 (18)</span></p> </td> <td style="width:47.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:50.05pt" width="63"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">102 (24)</span></p> </td> <td rowspan="2" style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:50.05pt" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">0.71 </span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">(95% CI [0.53, 0.96])</span></p> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">p-value=0.023</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:33.5pt"> <td style="width:82.85pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:33.5pt" width="110"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:8.0pt;   margin-left:4.9pt;page-break-after:avoid"><b><span lang="EN-GB">Estimated mPFS<sup>a</sup>   per IRF at 2 Year (%)</span></b></p> </td> <td style="width:66.8pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;   height:33.5pt" width="89"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">82.1</span></p> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">(95% CI [78.8, 85.0])</span></p> </td> <td style="width:58.65pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt" width="78"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">77.2</span></p> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">(95% CI [73.7, 80.4])</span></p> </td> <td style="width:57.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.5pt" width="77"> <p align="center" class="MsoNormal" style="margin-bottom:8.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">82.0 (95%   CI [77.8, 85.5])</span></p> </td> <td style="width:47.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.5pt" width="63"> <p align="center" class="MsoNormal" style="margin-bottom:8.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">75.3 (95%   CI [70.6, 79.3])</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:33.5pt"> <td style="width:82.85pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:33.5pt" width="110"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:8.0pt;   margin-left:4.9pt;page-break-after:avoid"><b><span lang="EN-GB">Overall Survival<sup>b</sup>   Number of deaths (%)</span></b></p> </td> <td style="width:66.8pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;   height:33.5pt" width="89"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">28 (4)</span></p> </td> <td style="width:58.65pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt" width="78"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">39 (6)</span></p> </td> <td style="width:73.7pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;   height:33.5pt" width="98"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">0.73</span></p> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">(95% CI [0.45, 1.18])</span></p> <p align="center" class="MsoNormal" style="margin-bottom:8.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">p-value=0.199</span></p> </td> <td style="width:57.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.5pt" width="77"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">14 (3)</span></p> </td> <td style="width:47.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:33.5pt" width="63"> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">26 (6)</span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;   height:33.5pt" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">0.51 </span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:windowtext">(95% CI [0.27, 0.97])</span></p> <p align="center" class="MsoNormal" style="margin-bottom:2.0pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">p-value=0.037</span></p> </td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">a</span></sup><span lang="EN-GB" style="font-size:9.0pt">At the time of analysis, the median modified PFS follow-up time for both arms was 24.6 months.</span></p><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">b</span></sup><span lang="EN-GB" style="font-size:9.0pt">Data from an interim OS analysis. </span></p><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:9.0pt">c</span></sup><span lang="EN-GB" style="font-size:9.0pt">p-value for Stage IV disease is not adjusted for multiplicity.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="EN-GB">Figure 1: Modified progression-free survival per IRF in the ITT population (ADCETRIS + AVD vs. ABVD)</span></b></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB"><img border="0" height="302" src="#image1" width="604"/></span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><a name="IDX"></a><b><span lang="EN-GB">Figure 2: Modified progression-free survival per IRF in patients with Stage IV disease (ADCETRIS + AVD vs. ABVD)</span></b></p><p class="MsoNormal" style="line-height:150%;page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB"><img border="0" height="284" src="#image2" width="598"/></span></p><p class="MsoNormal" style="text-autospace:none"><b></b></p><p class="MsoNormal"><span lang="EN-GB">Other secondary efficacy endpoints including CR rate and ORR at the end of randomisation regimen, CR rate at the end of first-line therapy, and the rate of PET negativity at the end of Cycle 2, duration of response (DOR), duration of complete remission (DOCR), disease-free survival (DFS) and event‑free survival (EFS) all trended in favour of ADCETRIS + AVD<a name="_Hlk519081083"> in both the ITT and Stage IV population</a>.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Pre‑specified subgroup analyses of modified PFS per IRF were performed for the ITT population including age, region, cancer stage at baseline, baseline extranodal sites, number of IPFP risk factors, baseline B symptoms, Cycle 2 PET assessment, Cycle 2 PET Deauville score, and receipt of alternative first-line medication (AFM). The analyses showed a consistent trend towards benefit for patients who received ADCETRIS + AVD compared with patients who received ABVD in most subgroups. The efficacy in elderly patient population (patients ≥ 60 years of age [n = 186] [HR = 1.00, 95% CI (0.58, 1.72)] and ≥ 65 years of age [n = 122] [HR = 1.01, 95% CI (0.53, 1.94)]) and patients with no extranodal sites (n = 445) (HR = 1.04, 95% CI [0.67, 1.62]) showed no clinically meaningful difference between the two arms.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Post‑hoc subgroup analyses of modified PFS per IRF for patients with Stage IV disease were performed including age, region, baseline extranodal sites, number of IPFP risk factors, baseline B symptoms, baseline ECOG status and gender. The analyses showed a consistent trend towards benefit for patients who received ADCETRIS + AVD compared with patients who received ABVD in most subgroups. P</span><span lang="EN-GB" style="color:windowtext">atients with Stage IV disease for whom extranodal disease was reported ([n = 722] [HR = 0.69, 95% CI (0.50, 0.94)]) showed an mPFS (per IRF) benefit. In patients with Stage IV disease for whom no extranodal disease was reported, n</span><span lang="EN-GB" style="color:windowtext">o benefit has been shown at time of analysis </span><span lang="EN-GB" style="color:windowtext">([n = 85] [HR = 1.49, 95% CI (0.51, 4.31)]). </span><span lang="EN-GB" style="color:windowtext">The significance of this finding in stage IV HL patients with no extranodal disease is not established due to small patient numbers and low event rates (14 events).</span><span lang="EN-GB" style="color:windowtext">The efficacy in elderly patients with Stage IV disease in the A + AVD arm (patients ≥ 60 years of age [n = 118] [HR = 0.80, 95% CI (0.42, 1.53)] and ≥ 65 years of age [n = 78] [HR = 0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with elderly patients in ITT population.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><a name="_Hlk519587500"><span lang="EN-GB">In the ITT population, 33% fewer patients treated with ADCETRIS + AVD in the ITT population received subsequent salvage chemotherapy (n = 66) and high-dose chemotherapy and transplant (n = 36) compared with those treated with ABVD (n = 99 and n = 54, respectively). In the Stage IV population, 35% fewer patients treated with ADCETRIS + AVD received subsequent salvage chemotherapy (n = 45) compared with those treated with ABVD (n = 69) and 22% fewer patients treated with ADCETRIS + AVD received high-dose chemotherapy and transplant (n = 29) compared with those treated with ABVD (n = 37).</span></a></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The European Organization for Research and Treatment of Cancer Quality of Life 30‑Item Questionnaire (EORTC‑QLQ‑C30) showed no clinically meaningful difference between the two arms in both the ITT and Stage IV population.</span></p><p class="MsoNormal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study SGN35‑005</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The efficacy and safety of ADCETRIS were evaluated in a randomised, double‑blind, placebo‑controlled, 2‑arm multicenter trial in 329 patients with HL at risk of relapse or progression following ASCT. Patients with known cerebral/meningeal disease, including history of PML were excluded from the study. See Table 8 for patient characteristics. Of the 329 patients, 165 patients were randomised to the treatment arm and 164 patients were randomised to the placebo arm. In the study, patients were to receive their first dose after recovery from ASCT (between days 30‑45 following ASCT). Patients were treated with 1.8 mg/kg of ADCETRIS or matching placebo intravenously over 30 minutes every 3 weeks for up to 16 cycles.</span></p><p class="MsoNormal"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Eligible patients were required to have at least one of the following risk factors: </span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol">·</span><span lang="EN-GB" style="font-size:11.0pt">HL that was refractory to frontline treatment</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="font-size: 11.0pt;font-family:Symbol">·</span><span lang="EN-GB" style="font-size:11.0pt">Relapsed or progressive HL that occurred &lt;12 months from the end of frontline treatment</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">Extranodal involvement at time of pre‑ASCT relapse, including extranodal extension of nodal masses into adjacent vital organs.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.5in"></p><p class="MsoNormal" style="page-break-before:always;page-break-after:avoid"><b><span lang="EN-GB">Table 8: Summary of baseline patient and disease characteristics in the phase 3 HL post‑ASCT Study<br/> <br/> </span></b></p><div align="center"> <table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:444.45pt;border-collapse:collapse;border:none" width="593"> <tr style="height:15.1pt"> <td style="width:215.95pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="288"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:112.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 165</span></b></p> </td> <td style="width:116.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 164</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33 years (18‑71)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">32 years (18‑76)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="288"> <p class="MsoNormal" style="text-indent:8.6pt"><span lang="EN-GB">Gender</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">76M   (46%)/89F (54%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97M   (59%)/67F (41%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="288"> <p class="MsoNormal" style="text-indent:8.6pt"><span lang="EN-GB">ECOG status</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">0</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">87   (53%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97   (59%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">1</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">77   (47%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">67   (41%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">2</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">1   (1%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="288"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt"><b><span lang="EN-GB">Disease characteristics</span></b></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of prior chemotherapy regimens (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (2‑8)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (2‑7)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median time from HL diagnosis to first dose (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18.7 mo   (6.1‑204.0)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18.8 mo   (7.4‑180.8)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Disease stage at initial diagnosis of HL</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage I</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">1   (1%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">5   (3%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage II</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">73   (44%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">61   (37%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage III</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">48   (29%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">45   (27%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage IV</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">43   (26%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">51   (31%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Unknown</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (1%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">PET scan Status prior to ASCT</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">FDG‑AVID</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">64   (39%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">51   (31%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">FDG‑NEGATIVE</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">57   (35%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">NOT DONE</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">45   (27%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Extranodal involvement at time of pre‑ASCT relapse</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">54   (33%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">53   (32%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">B symptoms</span><sup><span lang="EN-GB">a</span></sup></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">47   (28%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">40   (24%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Best response to salvage therapy pre‑ASCT<sup>b</sup></span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Complete   Response</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">61   (37%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">62   (38%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Partial   Response</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">57   (35%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stable Disease</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">47   (28%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">46   (28%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Refractory</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">99   (60%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97   (59%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Relapse   occurred &lt;12 months</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">53   (32%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">54   (33%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Relapse   occurred ≥ 12 months</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">13   (8%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">13   (8%)</span></p> </td> </tr> </table> </div><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:444.45pt;border-collapse:collapse;border:none" width="593"> <tr style="height:15.1pt"> <td style="width:215.95pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="288"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:112.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 165</span></b></p> </td> <td style="width:116.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 164</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33 years (18‑71)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">32 years (18‑76)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="288"> <p class="MsoNormal" style="text-indent:8.6pt"><span lang="EN-GB">Gender</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">76M   (46%)/89F (54%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97M   (59%)/67F (41%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="288"> <p class="MsoNormal" style="text-indent:8.6pt"><span lang="EN-GB">ECOG status</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">0</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">87   (53%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97   (59%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">1</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">77   (47%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">67   (41%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">2</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">1   (1%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="288"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt"><b><span lang="EN-GB">Disease characteristics</span></b></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of prior chemotherapy regimens (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (2‑8)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (2‑7)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median time from HL diagnosis to first dose (range)</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18.7 mo   (6.1‑204.0)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">18.8 mo   (7.4‑180.8)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Disease stage at initial diagnosis of HL</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage I</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">1   (1%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">5   (3%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage II</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">73   (44%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">61   (37%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage III</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">48   (29%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">45   (27%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stage IV</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">43   (26%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">51   (31%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Unknown</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">2   (1%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">PET scan Status prior to ASCT</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">FDG‑AVID</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">64   (39%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">51   (31%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">FDG‑NEGATIVE</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">57   (35%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">NOT DONE</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">45   (27%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Extranodal involvement at time of pre‑ASCT relapse</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">54   (33%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">53   (32%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">B symptoms</span><sup><span lang="EN-GB">a</span></sup></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">47   (28%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">40   (24%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Best response to salvage therapy pre‑ASCT<sup>b</sup></span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Complete   Response</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">61   (37%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">62   (38%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Partial   Response</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">57   (35%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">56   (34%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Stable Disease</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">47   (28%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">46   (28%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Refractory</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">99   (60%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">97   (59%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Relapse   occurred &lt;12 months</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">53   (32%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">54   (33%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:215.95pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="288"> <p class="MsoNormal" style="margin-left:19.6pt"><span lang="EN-GB">Relapse   occurred ≥ 12 months</span></p> </td> <td style="width:112.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="150"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">13   (8%)</span></p> </td> <td style="width:116.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">13   (8%)</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">For refractory disease, or upon progression or relapse after frontline therapy.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Stratification factors at randomisation.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The efficacy results are shown in Table 9. The primary endpoint of PFS was met and showed a difference in median PFS of 18.8 months in favour of the treatment arm.</span></p><p class="MsoNormal" style="margin-left:43.1pt;text-indent:-43.1pt"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 9: Efficacy results in HL patients at increased risk of relapse or progression following ASCT treated with 1.8 mg/kg of ADCETRIS every 3 weeks<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:459.4pt;border-collapse:collapse;border:none" width="613"> <tr style="height:39.0pt"> <td style="width:85.9pt;border:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;   height:39.0pt" width="115"></td> <td style="width:1.75in;border:solid windowtext 1.0pt;border-left:   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 165</span></b></p> </td> <td style="width:130.5pt;border:solid windowtext 1.0pt;border-left:   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt" width="174"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 164</span></b></p> </td> <td style="width:117.0pt;border:solid windowtext 1.0pt;border-left:   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt" width="156"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Stratified Hazard Ratio</span></b></p> </td> </tr> <tr style="height:19.3pt"> <td rowspan="4" style="width:85.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="115"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Progression   Free Survival<sup>a</sup> </span></b></p> </td> <td colspan="2" style="width:256.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="342"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median per IRF</span></b></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" valign="top" width="156"></td> </tr> <tr style="height:19.3pt"> <td style="width:1.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42.9 months</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [30.4, 42.9])</span></p> </td> <td style="width:130.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="174"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">24.1 months</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [11.5, -])</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" valign="top" width="156"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.57</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.40, 0.81])</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">Stratified log-rank test p=0.001</span></p> </td> </tr> <tr style="height:19.3pt"> <td colspan="2" style="width:256.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="342"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median per Investigator </span></b></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" valign="top" width="156"></td> </tr> <tr style="height:19.3pt"> <td style="width:1.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">Not reached</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [26.4, -])</span></p> </td> <td style="width:130.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="174"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15.8 months</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [8.5, -])</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" valign="top" width="156"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.5</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.36, 0.70])<sup>b</sup></span></p> </td> </tr> <tr style="height:19.3pt"> <td rowspan="2" style="width:85.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="115"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Overall   Survival</span></b></p> </td> <td colspan="2" style="width:256.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" width="342"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of deaths (%)</span></b></p> </td> <td style="width:117.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt" valign="top" width="156"></td> </tr> <tr style="height:25.75pt"> <td style="width:1.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">28 (17)</span></p> </td> <td style="width:130.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt" width="174"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">25 (15)</span></p> </td> <td style="width:117.0pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt" width="156"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1.15</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.67, 1.97]</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">At the time of the primary analysis, the median follow-up time for both arms was 30 months (range, 0 to 50). </span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Stratified log‑rank test was not performed for PFS per Investigator.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Pre‑specified subgroup analyses of PFS per IRF were performed by patients’ best response to pre‑ASCT salvage therapy, HL status after frontline therapy, age, gender, baseline weight, baseline ECOG performance status, number of treatments pre‑ASCT, geographic region, pre‑ASCT PET status, B symptom status after failure of frontline therapy, and pre‑ASCT extranodal disease status. The analyses showed a consistent trend towards benefit for patients who received ADCETRIS compared with patients who received placebo with the exception of patients ≥65 years of age (n = 8).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">No differences were observed in quality of life between the treatment and placebo arms. Medical resource utilization (MRU) analysis showed that hospitalizations and outpatient visits, as well as working days/other activities missed by patients and caregivers were lower with ADCETRIS compared with placebo in patients with HL at increased risk of relapse.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">An updated analysis conducted after 3 years of follow‑up showed a sustained PFS improvement per IRF (HR = 0.58 [95% CI (0.41, 0.81)]).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Post‑hoc Risk Factor Analyses</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Post‑hoc analyses were performed </span><span lang="EN-GB">to evaluate the impact of increased</span><span lang="EN-GB"> risk (number of risk factors) on clinical benefit (Table 10). </span><span lang="EN-GB">Representative risk factors for these analyses were:</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">HL that occurred &lt;12 months or HL that was refractory to frontline therapy</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">Best response of PR or SD to most recent salvage therapy as determined by CT and/or PET scanning </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">Extranodal disease at pre‑ASCT relapse</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">B symptoms at pre‑ASCT relapse</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">Two or more prior salvage therapies. </span></p><p class="MsoListParagraphCxSpLast"></p><p class="MsoNormal"><span lang="EN-GB">The results of these post‑hoc analyses suggest increased clinical benefit for patients with two or more risk factors but no difference based on any of the individual risk factors. No benefit in terms of PFS or OS has been observed in patients with one risk factor for relapse or progression.</span></p><p class="MsoNormal" style="margin-left:41.05pt;text-indent:-41.05pt"></p><p class="MsoNormal" style="margin-left:-4.5pt;text-indent:-.55pt;page-break-after: avoid"><b><span lang="EN-GB">Table 10: Summary of PFS per IRF and OS by number of risk factors in the phase 3 HL post‑ASCT Study <br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none" width="613"> <tr> <td colspan="7" style="width:459.9pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="613"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">                                               Progression   Free Survival per IRF</span></b></p> </td> </tr> <tr> <td rowspan="2" style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"></td> <td colspan="2" style="width:128.85pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="172"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors</span></b><span lang="EN-GB"> <b>= 1</b></span></p> </td> <td colspan="2" style="width:136.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="182"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors ≥ 2</span></b></p> </td> <td colspan="2" style="width:1.75in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors ≥ 3</span></b></p> </td> </tr> <tr> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 21</span></b></p> </td> <td style="width:52.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 28</span></b></p> </td> <td style="width:83.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="112"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 144</span></b></p> </td> <td style="width:52.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 136</span></b></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 82</span></b></p> </td> <td style="width:49.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 84</span></b></p> </td> </tr> <tr> <td style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Number of   patients with disease progression or death<sup>a </sup></span><span lang="EN-GB">(%)</span></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">9 (43)</span></p> </td> <td style="width:52.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">7 (25)</span></p> </td> <td style="width:83.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="112"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">51 (35)</span></p> </td> <td style="width:52.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">68 (50)</span></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">32 (39)</span></p> </td> <td style="width:49.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">49 (58)</span></p> </td> </tr> <tr> <td style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Stratified   Hazard Ratio </span></p> </td> <td colspan="2" style="width:128.85pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="172"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1.65</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.60, 4.55])<sup>b</sup></span></p> </td> <td colspan="2" style="width:136.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="182"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.49</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.34, 0.71])</span></p> </td> <td colspan="2" style="width:1.75in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.43 </span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.27, 0.68])</span></p> </td> </tr> <tr> <td colspan="7" style="width:459.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="613"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Overall Survival </span></b></p> </td> </tr> <tr> <td rowspan="2" style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"></td> <td colspan="2" style="width:128.85pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="172"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors = 1</span></b></p> </td> <td colspan="2" style="width:136.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="182"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors ≥ 2</span></b></p> </td> <td colspan="2" style="width:1.75in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Number of Risk Factors ≥ 3</span></b></p> </td> </tr> <tr> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 21</span></b></p> </td> <td style="width:52.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 28</span></b></p> </td> <td style="width:83.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="112"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 144</span></b></p> </td> <td style="width:52.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 136</span></b></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 82</span></b></p> </td> <td style="width:49.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Placebo</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 84</span></b></p> </td> </tr> <tr> <td style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Number of   deaths<sup>c </sup></span><span lang="EN-GB">(%)</span></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">5 (24)</span></p> </td> <td style="width:52.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (4)</span></p> </td> <td style="width:83.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="112"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">23 (16)</span></p> </td> <td style="width:52.7pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="70"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">24 (18)</span></p> </td> <td style="width:76.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="102"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15 (18)</span></p> </td> <td style="width:49.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">16 (19)</span></p> </td> </tr> <tr> <td style="width:.95in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="91"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Stratified   Hazard Ratio </span></p> </td> <td colspan="2" style="width:128.85pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="172"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">7.94</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.93, 68.06])<sup>b</sup></span></p> </td> <td colspan="2" style="width:136.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="182"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.94</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.53, 1.67])</span></p> </td> <td colspan="2" style="width:1.75in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.92</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(95% CI [0.45, 1.88])</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Death without either prior progression or more than one missed assessment visit.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Indicates results from non-stratified analysis.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">c.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Events are death due to any cause.</span></p><p class="MsoNormal" style="margin-left:41.05pt;text-indent:-41.05pt;page-break-after: avoid"></p><p class="MsoNormal"><span lang="EN-GB">At the time of the updated analysis (3 years of follow-up) for patients with 2 or more risk factors, the hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3 and 4).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Figure 3: Kaplan-Meier Plot of PFS per IRF in Patients with ≥ 2 Risk Factors</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB"><img border="0" height="299" id="Picture 38" src="#image3" width="605"/></span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Figure 4: Kaplan-Meier Plot of PFS per Investigator in Patients with ≥ 2 Risk Factors</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB"><img border="0" height="299" id="Picture 79" src="#image4" width="605"/></span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study SG035‑0003</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">The efficacy and safety of </span><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt"> as a single agent was evaluated in a pivotal open-label, single‑arm, multicenter study in 102 patients with relapsed or refractory HL. See Table 11 below for a summary of baseline patient and disease characteristics. </span></p><p class="Paragraph" style="margin-bottom:0in"><i><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></i></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><b><span lang="EN-GB" style="font-size:11.0pt">Table 11: Summary of baseline patient and disease characteristics in the phase 2 relapsed or refractory HL study<br/> <br/> </span></b></p><div align="center"> <table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:444.45pt;border-collapse:collapse;border:none" width="593"> <tr style="height:15.1pt"> <td style="width:309.65pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="413"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><a name="OLE_LINK4"></a><a name="RANGE!A1"></a><b><span lang="EN-GB">Patient   characteristics</span></b></p> </td> <td style="width:134.8pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><a name="OLE_LINK3"><b><span lang="EN-GB">n = 102</span></b></a></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">31 years (15‑77)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="413"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">48M (47%)/54F (53%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="413"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42 (41%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">60 (59%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior ASCT</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">102 (100%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior chemotherapy Regimens</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.5 (1‑13)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Time from ASCT to first post-transplant relapse</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">6.7 mo (0‑131)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Histologically confirmed CD30‑expressing   disease</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">102 (100%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="413"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Primary Refractory to frontline therapy<sup>a</sup></span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">72 (71%)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Refractory to most recent therapy</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">43 (42%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Baseline B symptoms</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">35 (33%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage III at initial diagnosis</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">27 (26%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage IV at initial diagnosis</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">20 (20%)</span></p> </td> </tr> </table> </div><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:444.45pt;border-collapse:collapse;border:none" width="593"> <tr style="height:15.1pt"> <td style="width:309.65pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="413"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><a name="OLE_LINK4"></a><a name="RANGE!A1"></a><b><span lang="EN-GB">Patient   characteristics</span></b></p> </td> <td style="width:134.8pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><a name="OLE_LINK3"><b><span lang="EN-GB">n = 102</span></b></a></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">31 years (15‑77)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="413"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">48M (47%)/54F (53%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="413"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42 (41%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">60 (59%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior ASCT</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">102 (100%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior chemotherapy Regimens</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.5 (1‑13)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Time from ASCT to first post-transplant relapse</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">6.7 mo (0‑131)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Histologically confirmed CD30‑expressing   disease</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">102 (100%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="413"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Primary Refractory to frontline therapy<sup>a</sup></span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">72 (71%)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Refractory to most recent therapy</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">43 (42%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Baseline B symptoms</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">35 (33%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage III at initial diagnosis</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">27 (26%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:309.65pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="413"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage IV at initial diagnosis</span></p> </td> <td style="width:134.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">20 (20%)</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:22.5pt;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Primary refractory HL is defined as a failure to achieve a complete remission to, or progressed within 3 months of completing frontline therapy.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Eighteen (18) patients (18%) received 16 cycles of </span><span lang="EN-GB" style="font-size:11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt">; and the median number of cycles received was 9 (ranging from 1 to 1</span><span lang="EN-GB" style="font-size:11.0pt">6).<sup> </sup></span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Response to treatment with </span><span lang="EN-GB" style="font-size: 11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt"> was assessed by Independent Review Facility (IRF) using the Revised Response Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data. Response assessments were performed at cycles 2, 4, 7, 10, 13, and 16 with PET at cycles 4 and 7.</span></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">The objective response rate (ORR) per IRF assessment was 75% (76 of 102 patients in the intent‑to‑treat [ITT] set) and tumour reduction was achieved in 94% of patients. Complete remission (CR) was 33% (34 of 102 patients in the ITT set). The median overall survival (OS) is 40.5 months (the median observation time (time to death or last contact) from first dose was 35.1 months (range 1.8 to 72.9+ months). The estimated overall survival rate at 5 years was 41% (95% CI [31%, 51%]).<a name="OLE_LINK8"></a><a name="OLE_LINK9"> The investigator assessments were generally consistent with the independent review of the scans.</a> </span><span lang="EN-GB" style="font-size:11.0pt">Of the patients treated, 8 responding patients went on to receive an allogeneic SCT. </span><span lang="EN-GB" style="font-size:11.0pt">For further efficacy results see Table 12. </span></p><p class="MsoNormal" style="margin-left:131.75pt;text-indent:-131.75pt"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 12: Efficacy results in relapsed or refractory Hodgkin lymphoma patients treated with 1.8 mg/kg of </span></b><b><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> every 3 weeks<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none" width="600"> <tr style="height:15.1pt"> <td nowrap="" style="width:188.1pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Best   clinical response</span></b><b><sup></sup></b><b><span lang="EN-GB">(n = 102</span></b><sup></sup><b><span lang="EN-GB">)</span></b></p> </td> <td nowrap="" style="width:1.95in;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">IRF n (%)</span></b></p> </td> <td nowrap="" style="width:121.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Objective response rate (CR + PR)</span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">76 (75)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">64.9, 82.6</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">            Complete remission (CR)</span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">34 (33)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">24.3, 43.4</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">            Partial remission (PR)</span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42 (41)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">98 (96)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">90.3, 98.9</span></p> </td> </tr> <tr style="height:14.8pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.8pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Duration   of response </span></b></p> </td> <td style="width:1.95in;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.8pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median per IRF </span></b></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.8pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Objective response rate (CR + PR)<sup>a</sup></span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">6.7 months </span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.6, 14.8</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:188.1pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Complete remission (CR)</span></p> </td> <td nowrap="" style="width:1.95in;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">27.9 months</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">10.8, NE<sup>b</sup> </span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:188.1pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="251"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Overall   survival </span></b></p> </td> <td style="width:1.95in;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:7.5pt"> <td style="width:188.1pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="251"> <p class="MsoNormal" style="margin-left:9.0pt;page-break-after:avoid"><span lang="EN-GB">Median</span></p> </td> <td style="width:1.95in;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">40.5 months</span><b><sup></sup></b></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">28.7, 61.9</span></p> </td> </tr> <tr style="height:7.5pt"> <td style="width:188.1pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="251"> <p class="MsoNormal" style="margin-left:9.0pt;page-break-after:avoid"><span lang="EN-GB">Estimated 5‑year OS Rate</span></p> </td> <td style="width:1.95in;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="187"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">41%</span></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">31%, 51%</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">The range of DOR was 1.2+ months to 43+ months and the median follow-up time from first dose for patients who achieved objective response (OR) per IRF was 9.0 months.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><sup><span lang="EN-GB" style="font-size: 11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Not estimable.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">An exploratory intra‑patient analysis showed that approximately 64% of the HL patients treated with ADCETRIS as part of the SG035‑0003 clinical study experienced an improvement in clinical benefit as measured by longer progression free survival (PFS) compared with their most recent prior line of therapy. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Of the 35 patients (33%) who had B symptoms at baseline, 27 patients (77%) experienced resolution of all B symptoms at a median time of 0.7 months from initiation of </span><span lang="EN-GB" style="font-size:11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt">.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Data in HL Patients Who Are Not Stem Cell Transplant (SCT) Candidates</span></p><p class="TableText" style="margin-bottom:0in"></p><p class="TableText" style="margin-bottom:0in;page-break-after:avoid"><span style="font-size:11.0pt">Study‑C25007 </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">A phase 4 single-arm study was conducted in patients with relapsed or refractory HL (n = 60) who had received at least one prior chemotherapeutic regimen and at the time of treatment initiation with ADCETRIS were not considered candidates for SCT or multiagent chemotherapy. The median number of cycles was 7 (range 1 to 16 cycles). Patients were treated with 1.8 mg/kg of ADCETRIS every 3 weeks. Per IRF, the objective response rate (ORR) in the ITT population was 50% (95% CI, 37; 63%). A best overall response of CR was reported for 7 patients (12%); PR was reported for 23 patients (38%). Among these 30 patients, the median time to response, defined as the time from first dose to the soonest of PR or CR, was 6 weeks (range, 5 to 39 weeks). The median time to best overall response, defined as the time from first dose to the clinical best response of CR or PR, was 11 weeks (range, 5 to 60 weeks). Twenty‑eight patients (47%) went on to receive SCT after a median of 7 cycles (range, 4 to 16 cycles) of ADCETRIS treatment. The 32 patients (53%) who did not receive subsequent SCT also received ADCETRIS for a median of 7 cycles (range, 1 to 16 cycles). </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Of the study’s 60 patients, 49 patients (82%) received &gt; 1 prior cancer-related treatment and 11 patients (18%) received 1 prior cancer-related treatment. Per IRF, the ORR was 51% (95% CI [36%, 66%]) for the patients who had received &gt; 1 prior cancer-related treatment and 45% (95% CI [17%, 77%]) for the patients who had received 1 prior cancer-related treatment. For the patients who received &gt; 1 prior cancer-related treatment, a best overall response of CR was reported for 6 patients (12%); PR was reported for 19 patients (39%). For the patients who received 1 prior cancer-related treatment, CR was reported for 1 patient (9%) and PR was reported for 4 patients (36%). Out of the 49 patients receiving &gt; 1 line of prior treatment, 22 patients (45%) received subsequent SCT; of the 11 patients who had received 1 prior treatment, 6 patients (55%) received subsequent SCT.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Data were also collected from patients (n = 15) in phase 1 dose escalation and clinical pharmacology studies, and from patients (n = 26) in a NPP, with relapsed or refractory HL who had not received an ASCT, and who were treated with 1.8 mg/kg of ADCETRIS every 3 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Baseline patient characteristics showed failure from multiple prior chemotherapy regimens (median of 3 with a range of 1 to 7) before first administration with ADCETRIS. Fifty nine percent (59%) of patients had advanced stage disease (Stage III or IV) at initial diagnosis. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Results from these phase 1 studies and from the NPP experience showed, that in patients with relapsed or refractory HL without prior ASCT, clinically meaningful responses can be achieved as evidenced by an investigator-assessed, objective response rate of 54% and a complete remission rate of 22% after a median of 5 cycles of ADCETRIS. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study SGN35‑006 (Retreatment Study)</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">The efficacy of retreatment in patients who had previously responded (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2, open-label, multicenter trial. Twenty patients with relapsed or refractory HL received a starting dose of 1.8 mg/kg and one patient received a starting dose of 1.2 mg/kg of ADCETRIS administered intravenously over 30 minutes every 3 weeks. The median number of cycles was 7 (range, 2 to 37 cycles).</span><span lang="EN-GB" style="font-size:11.0pt">Of the 20 evaluable patients with HL, 6 patients (30%) achieved a CR and 6 patients (30%) achieved a PR with ADCETRIS retreatment, for an ORR of 60%. </span><span lang="EN-GB" style="font-size:11.0pt">The median duration of response was 9.2 and 9.4 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB">Systemic anaplastic large cell lymphoma</span></i></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Study SGN35‑014</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">The efficacy and safety of ADCETRIS were evaluated in a randomised, double-blind, double-dummy, active-controlled, multicenter trial of 452 patients with previously untreated CD30+ PTCL in combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP). </span><span style="font-size:11.0pt">For enrollment, the trial required CD30 expression ≥10% per immunohistochemistry. </span><span lang="EN-GB" style="font-size:11.0pt">Only patients with CD30+ PTCLs who were eligible for a </span><span lang="EN-GB" style="font-size:11.0pt">cyclophosphamide [C], doxorubicin [H], vincristine [O] and prednisone [P]</span><span lang="EN-GB" style="font-size:11.0pt"> (CHOP)-based regimen were included.</span><span style="font-size:11.0pt"> The combination of ADCETRIS + CHP has not been studied in all PTCL subtypes. See Table 13 for enrolled PTCL subtypes. </span><span lang="EN-GB" style="font-size:11.0pt">Of the 452 patients, 226 were randomised to treatment with ADCETRIS + CHP and 226 patients were randomised to treatment with CHOP. Randomisation was stratified by ALK-positive sALCL versus all other subtypes and by the International Prognostic Index (IPI) score. Patients were treated with ADCETRIS administered as an intravenous infusion over 30 minutes on day 1 of each 21‑day cycle for 6 to 8 cycles + CHP. The median number of cycles received was 6 (range, 1 to 8 cycles); 70% of patients received 6 cycles of treatment, and 18% received 8 cycles of treatment. Table 13 provides a summary of baseline patient and disease characteristics.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><a name="_Ref525816436"><b><span lang="EN-GB">Table </span></b></a><b><span lang="EN-GB">13: Summary of baseline patient and disease characteristics in the phase 3 previously untreated PTCL study (ITT and sALCL)</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:459.4pt;border-collapse:collapse;border:none" width="613"> <thead> <tr> <td style="width:189.45pt;border:solid windowtext 1.0pt;    border-right:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td colspan="2" style="width:133.95pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="179"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">ITT Population </span></b></p> </td> <td colspan="2" style="width:136.0pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="181"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">sALCL Population<sup>b</sup></span></b></p> </td> </tr> <tr> <td style="width:189.45pt;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Patient    characteristics</span></b></p> </td> <td style="width:67.65pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">ADCETRIS + CHP</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">n=226</span></b></p> </td> <td style="width:66.3pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">CHOP</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">n=226</span></b></p> </td> <td style="width:69.55pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">ADCETRIS + CHP</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">n=162</span></b></p> </td> <td style="width:66.45pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="bottom" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">CHOP</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">n=154</span></b></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Median    age (range)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">58.0 (18‑85)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">58.0 (18‑83)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">55.0 (18-85)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">54.0 (18-83)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Patients    ≥ 65 years old (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">69 (31)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">70 (31)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">38 (23)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">36 (23)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Male sex,    n (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">133 (59)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">151 (67)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">95 (59)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">110 (71)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">ECOG    status, n (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">84 (37)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">93 (41)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">58 (36)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">53 (34)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">90 (40)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">86 (38)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">62 (38)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">61 (40)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> <td style="width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">51 (23)</span></p> </td> <td style="width:66.3pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">47 (21)</span></p> </td> <td style="width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">41 (25)</span></p> </td> <td style="width:66.45pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">40 (26)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Disease    characteristics</span></b></p> </td> <td style="width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Diagnosis, per local assessment, n (%)<sup>a</sup></span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">sALCL</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">162 (72)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">154 (68)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">162 (100)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">154 (100)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.4in;page-break-after:avoid"><span lang="EN-GB">ALK-positive</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">49 (22)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">49 (22)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">49 (30)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">49 (32)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.4in;page-break-after:avoid"><span lang="EN-GB">ALK-negative</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">113 (50)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">105 (46)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">113 (70)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">105 (68)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="FR">Peripheral T-cell lymphoma (PTCL-NOS)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">29 (13)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">43 (19)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Angioimmunoblastic T-cell lymphoma (AITL)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">30 (13)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">24 (11)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Adult T-cell leukemia/lymphoma (ATLL)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">4 (2)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">3 (1)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Enteropathy-associated T-cell lymphoma (EATL)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">1 (0)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">2 (1)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Median time from diagnosis to first dose, months (range)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">0.8 (0, 19)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">0.9 (0, 10)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">0.8 (0, 19)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">0.9 (0, 10)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Disease stage at initial diagnosis of PTCL, n (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Stage I</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">12 (5)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">9 (4)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">12 (7)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">7 (5)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Stage II</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">30 (13)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">37 (16)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">22 (14)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">27 (18)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Stage III</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">57 (25)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">67 (30)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">29 (18)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">46 (30)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Stage IV</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">127 (56)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">113 (50)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">99 (61)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">74 (48)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">IPI score </span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">8 (4)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">16 (7)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">7 (4)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">14 (9)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">45 (20)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">32 (14)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">34 (21)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">18 (12)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">74 (33)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">78 (35)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">58 (36)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">60 (39)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">3</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">66 (29)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">66 (29)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">37 (23)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">40 (26)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">4</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">29 (13)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">25 (11)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">22 (14)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">16 (10)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">5</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">4 (2)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">9 (4)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">4 (2)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">6 (4)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Extranodal involvement at time of diagnosis, n (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-top:0in;margin-right:.2in;margin-bottom:    0in;margin-left:.2in;margin-bottom:.0001pt;page-break-after:avoid"><span lang="EN-GB">≤ 1 site</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">142 (63)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">146 (65)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">94 (58)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">95 (62)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">&gt;1 site</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">84 (37)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">80 (35)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">68 (42)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">59 (38)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.1in;page-break-after:avoid"><span lang="EN-GB">Baseline bone marrow biopsy-lymphoma involvement, n (%)</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"></p> </td> </tr> <tr> <td style="width:189.45pt;border:none;border-left:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">Yes</span></p> </td> <td style="width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">30 (13)</span></p> </td> <td style="width:66.3pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">34 (15)</span></p> </td> <td style="width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">15 (9)</span></p> </td> <td style="width:66.45pt;border:none;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">13 (8)</span></p> </td> </tr> <tr> <td style="width:189.45pt;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="253"> <p class="MsoNormal" style="margin-left:.2in;page-break-after:avoid"><span lang="EN-GB">No</span></p> </td> <td style="width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">196 (87)</span></p> </td> <td style="width:66.3pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="88"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">192 (85)</span></p> </td> <td style="width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="93"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">147 (91)</span></p> </td> <td style="width:66.45pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><span lang="EN-GB">141 (92)</span></p> </td> </tr> </thead> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:17.85pt;text-indent:-17.85pt"><sup><span lang="EN-GB" style="font-size:9.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">      As per the 2008 WHO classification.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:17.85pt;text-indent:-17.85pt"><sup><span lang="EN-GB" style="font-size:9.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">      For patients with locally-diagnosed sALCL.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">The primary endpoint in SGN35‑014 was PFS per IRF, defined as the time from the date of randomisation to the date of first documentation of progressive disease, death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease, whichever occurs first. Receipt of post‑treatment consolidative radiotherapy, post-treatment chemotherapy for the purpose of mobilising peripheral blood stem cells, or consolidative autologous or allogeneic stem cell transplant were not considered as disease progression or as having started new anticancer therapy.</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">Key secondary endpoints included PFS per IRF for patients with centrally-confirmed sALCL, CR rate per IRF </span><span style="font-size:11.0pt">following the completion of study treatment</span><span lang="EN-GB" style="font-size:11.0pt">, OS and ORR per IRF </span><span style="font-size:11.0pt">following the completion of study treatment</span><span lang="EN-GB" style="font-size:11.0pt"> which were tested by a fixed sequence testing procedure following the statistical significance of PFS per IRF. </span></p><p class="Default"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The primary endpoint and alpha-protected, key secondary endpoints, which were evaluated hierarchically, were met. The median PFS per IRF for the ITT population was 48.2 months on the ADCETRIS + CHP arm versus 20.8 months on the CHOP arm. The stratified hazard ratio was 0.71 (95% CI: 0.54; 0.93, p=0.011), indicating a 29% reduction in the risk of PFS events for ADCETRIS + CHP versus CHOP. </span><span lang="EN-GB">For overall survival, the stratified hazard ratio was </span><span lang="EN-GB" style="color:windowtext">0.66</span><span lang="EN-GB"> (95% CI: </span><span lang="EN-GB" style="color:windowtext">0.46; 0.95, p=0.024),</span><span lang="EN-GB"> a 34% reduction in the risk of OS events for ADCETRIS + CHP versus CHOP. </span></p><p class="MsoCaption" style="margin:0in;text-indent:0in;page-break-after:auto"><a name="_Hlk7682306"></a></p><p class="MsoCaption" style="margin:0in;text-indent:0in;page-break-after:auto"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; font-weight:normal'>PFS per IRF for patients with centrally-confirmed sALCL was a pre-specified key secondary endpoint. The median PFS per IRF was 55.7 months on the ADCETRIS + CHP arm versus 54.2 months on the CHOP arm</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif; font-weight:normal'>. The stratified hazard ratio was 0.59 (95% CI: 0.42; 0.84), compatible with a statistically significant 41% reduction in the risk of PFS events for ADCETRIS + CHP versus CHOP (p‑value=0.003), see Figure 5 and Table 14.</span></p><p class="MsoCaption" style="margin:0in;text-indent:0in;page-break-after:auto"></p><p class="MsoCaption" style="margin:0in;text-indent:0in;page-break-after:auto"><span style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Subgroup analyses were performed for patients with locally-diagnosed sALCL. For overall survival, the stratified hazard ratio was </span><span style='font-size:11.0pt; font-family:"Times New Roman",serif;color:windowtext;font-weight:normal'>0.54</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif; color:windowtext;font-weight:normal'>0.34; 0.87),</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif;font-weight:normal'> a 46% reduction in the risk of OS events for ADCETRIS + CHP versus CHOP, see Figure 6. At the end of treatment, the CR rate by IRF assessment was 71.0% for patients on the ADCETRIS + CHP arm compared with 53.2% for patients on the CHOP arm with a difference of 17.7% (95% CI: 7.2%; 28.3%). At the end of treatment, the ORR rate by IRF assessment was 87.7% for patients on the ADCETRIS + CHP arm compared with 70.8% for patients on the CHOP arm with a difference of 16.9% (95% CI: 8.1%; 25.7%). In the subgroup of patients with ALK+ sALCL and ALK- sALCL the stratified hazard ratio for PFS per IRF was </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext; font-weight:normal'>0.29</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif; font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family: "Times New Roman",serif;color:windowtext;font-weight:normal'>0.11; 0.79) and 0.65</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif; color:windowtext;font-weight:normal'>0.44; 0.95), respectively. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 14: Efficacy results in patients with previously untreated sALCL with 1.8 mg/kg of ADCETRIS on day 1 of a 3‑week cycle </span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.35pt;border-collapse:collapse;border:none" width="587"> <tr style="height:30.35pt"> <td style="width:219.9pt;border:solid black 1.0pt;   padding:0in 0in 0in 0in;height:30.35pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:5.1pt;text-align:left;   line-height:normal;page-break-after:avoid"></p> </td> <td colspan="2" style="width:112.5pt;border:solid black 1.0pt;   border-left:none;padding:0in 0in 0in 0in;height:30.35pt" valign="top" width="150"> <p class="TableParagraph" style="margin-top:0in;margin-right:15.35pt;   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;   line-height:125%;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>ADCETRIS + CHP</span></b></p> <p class="TableParagraph" style="margin-top:0in;margin-right:15.35pt;   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;   line-height:125%;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>n=162<sup>a</sup></span></b></p> </td> <td style="width:1.5in;border:solid black 1.0pt;   border-left:none;padding:0in 0in 0in 0in;height:30.35pt" valign="top" width="144"> <p class="TableParagraph" style="margin-top:0in;margin-right:15.35pt;   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;   line-height:125%;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>CHOP</span></b></p> <p class="TableParagraph" style="margin-top:0in;margin-right:15.35pt;   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;   line-height:125%;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>n=154<sup>a</sup></span></b></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="4" style="width:440.4pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="bottom" width="587"> <p align="left" class="TableParagraph" style="margin-left:7.25pt;text-align:left;   text-indent:5.75pt;line-height:normal;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>PFS per IRF</span></b></p> </td> </tr> <tr style="height:15.8pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.8pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Number   of patients with a PFS event, n (%)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.8pt" valign="top" width="150"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>56 (34)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:15.8pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>73 (48)</span></p> </td> </tr> <tr style="height:17.6pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:17.6pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Median   PFS, months (95% CI)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:17.6pt" valign="top" width="150"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>55.66 (48.20, NE)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:17.6pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>54.18 (13.44, NE)</span></p> </td> </tr> <tr style="height:15.8pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.8pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Hazard   ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.8pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>0.59 (0.42, 0.84)</span></p> </td> </tr> <tr style="height:15.0pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.0pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>p-value<sup>c</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.0pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>0.0031</span></p> </td> </tr> <tr style="height:15.0pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.0pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:13.0pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>Estimated   PFS (95% CI)</span></b><sup><span style='font-family:"Times New Roman",serif'>d</span></sup><b><span style='font-family:"Times New Roman",serif'> at:</span></b></p> </td> <td style="width:110.25pt;border-top:none;border-left:   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.0pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"></p> </td> <td colspan="2" style="width:110.25pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.0pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"></p> </td> </tr> <tr style="height:29.75pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:29.75pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>6   months</span></p> </td> <td style="width:110.25pt;border-top:none;border-left:   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:29.75pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>88.0% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(81.8%, 92.2%)</span></p> </td> <td colspan="2" style="width:110.25pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:29.75pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>68.4% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(60.3%, 75.2%)</span></p> </td> </tr> <tr style="height:26.6pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:26.6pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>12   months</span></p> </td> <td style="width:110.25pt;border-top:none;border-left:   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:26.6pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>78.7% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(71.4%, 84.4%)</span></p> </td> <td colspan="2" style="width:110.25pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:26.6pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>60.3% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(51.9%, 67.6%)</span></p> </td> </tr> <tr style="height:27.05pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>24   months</span></p> </td> <td style="width:110.25pt;border-top:none;border-left:   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>68.4% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(60.4%, 75.2%)</span></p> </td> <td colspan="2" style="width:110.25pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>53.9% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(45.5%, 61.5%)</span></p> </td> </tr> <tr style="height:27.05pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:26.5pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>36   months</span></p> </td> <td style="width:110.25pt;border-top:none;border-left:   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>65.5% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(57.1%, 72.7%)</span></p> </td> <td colspan="2" style="width:110.25pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:27.05pt" valign="top" width="147"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>50.2% </span></p> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>(41.6%, 58.1%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="4" style="width:440.4pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="bottom" width="587"> <p align="left" class="TableParagraph" style="margin-top:0in;margin-right:38.55pt;   margin-bottom:0in;margin-left:13.0pt;margin-bottom:.0001pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>OS</span></b><sup><span style='font-family:"Times New Roman",serif'>e</span></sup></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Number of deaths (%)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="150"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>29 (18)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:15.1pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>44 (29)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Median OS, months (95% CI)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="150"> <p class="TableParagraph" style="margin-left:.25in;line-height:11.5pt;   page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>NE   (NE, NE)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:15.1pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>NE (NE, NE)</span></p> </td> </tr> <tr style="height:17.6pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:17.6pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>Hazard ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:17.6pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>0.54 (0.34, 0.87)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>p-value<sup>c, f</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>0.0096</span></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="4" style="width:440.4pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="bottom" width="587"> <p align="left" class="TableParagraph" style="margin-left:13.0pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>CR   Rate</span></b><sup><span style='font-family:"Times New Roman",serif'>g</span></sup></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>% (95% CI)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="150"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>71% (63.3%, 77.8%)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:15.1pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>53% (45.0%, 61.3%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>0.0004</span></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="4" style="width:440.4pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="587"> <p align="left" class="TableParagraph" style="margin-left:13.0pt;text-align:left;   line-height:11.5pt;page-break-after:avoid"><b><span style='font-family:"Times New Roman",serif'>ORR</span></b><sup><span style='font-family:"Times New Roman",serif'>g</span></sup></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>% (95% CI)</span></p> </td> <td colspan="2" style="width:112.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="150"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>88% (81.6%, 92.3%)</span></p> </td> <td style="width:1.5in;border-top:none;border-left:none;   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;   height:15.1pt" valign="top" width="144"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>71% (62.9%, 77.8%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:219.9pt;border:solid black 1.0pt;   border-top:none;padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="293"> <p align="left" class="TableParagraph" style="margin-left:.2in;text-align:left;   text-indent:12.1pt;line-height:normal;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan="3" style="width:220.5pt;border-top:none;   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;   padding:0in 0in 0in 0in;height:15.1pt" valign="top" width="294"> <p class="TableParagraph" style="line-height:11.5pt;page-break-after:avoid"><span style='font-family:"Times New Roman",serif'>&lt;0.0001</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="293"></td> <td style="border:none" width="147"></td> <td style="border:none" width="3"></td> <td style="border:none" width="144"></td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:9.0pt">CR=complete remission; IRF=Independent Review Facility; NE: Not estimable; ORR=objective response rate; PFS=progression-free survival.</span></p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">a</span>PFS per IRF is calculated using patients with centrally-confirmed sALCL, with n=163 patients in A+CHP arm and n=151 in CHOP arm. OS, CR, and ORR are calculated using patients with locally-diagnosed sALCL</p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">b</span>Hazard ratio (A+CHP/CHOP) and 95% confidence intervals are based on a stratified Cox’s proportional hazard regression model with stratification factors (ALK-positive sALCL versus all others and International Prognostic Index [IPI] score at baseline). Hazard ratio &lt;1 favours A+CHP arm.</p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">c</span>p-value is calculated using a stratified log-rank test.</p><p class="TableFootnoteLetter"><span style="color:black">d</span>PFS rate is estimated using Kaplan-Meier methods and 95% CI is calculated using the complementary log-log</p><p class="TableFootnoteLetter" style="margin-left:0in;text-indent:17.85pt">transformation method.</p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">e</span>Median OS follow-up in the A+CHP arm was 38.5 months; in the CHOP arm was 41.0 months.</p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">f</span>p-value is not adjusted for multiplicity. </p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">g</span>Response per 2007 International Working Group Criteria at end of treatment.</p><p class="TableFootnoteLetter" style="margin-left:17.85pt;text-indent:-17.85pt; page-break-after:avoid"><span style="color:black">h</span>p-value is calculated using a stratified Cochran-Mantel-Haenszel test.</p><p class="MsoNormal"> </p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><b><span style="font-size:11.0pt">Figure 5: </span></b><b><span style="font-size:11.0pt">Progression-free survival per IRF in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span style="font-size:11.0pt"><img border="0" height="416" src="#image5" width="605"/></span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><b><span style="font-size:11.0pt">Figure 6: </span></b><b><span style="font-size:11.0pt">Overall survival in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal"><img border="0" height="340" src="#image6" width="604"/></p><p class="MsoCaption" style="margin:0in;text-indent:0in;page-break-after:auto"><span style='font-size:9.0pt;font-family:"Times New Roman",serif;font-weight:normal'>*p-value for overall survival is not adjusted for multiplicity.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">Study SG035‑0004</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt">The efficacy and safety of </span><span lang="EN-GB" style="font-size:11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt"> as a single agent was evaluated in an open-label, single‑arm, multicenter study in 58 patients with relapsed or refractory sALCL. See Table 15 below for a summary of baseline patient and disease characteristics. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><b><span lang="EN-GB" style="font-size:11.0pt">Table 15: Summary of baseline patient and disease characteristics in the phase 2 relapsed or refractory sALCL study<br/> <br/> </span></b></p><div align="center"> <table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:6.25in;border-collapse:collapse;border:none" width="600"> <tr style="height:23.65pt"> <td style="width:288.05pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:161.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 58</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">52 years (14‑76)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="384"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33M (57%)/25F (43%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="384"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status<sup>a</sup></span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">19 (33%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">38 (66%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior ASCT</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15 (26%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior chemotherapy Regimens (range)</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (1‑6)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Histologically confirmed CD30‑expressing   disease</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">57 (98%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Anaplastic lymphoma kinase (ALK)-negative disease</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42 (72%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="384"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Primary Refractory to frontline therapy<sup>b</sup></span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">36 (62%)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Refractory to most recent therapy</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">29 (50%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Relapsed to most recent therapy</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">29 (50%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Baseline B symptoms</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">17 (29%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage III at initial diagnosis</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">8 (14%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage IV at initial diagnosis</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">21 (36%)</span></p> </td> </tr> </table> </div><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:6.25in;border-collapse:collapse;border:none" width="600"> <tr style="height:23.65pt"> <td style="width:288.05pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:161.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 58</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age, years (range)</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">52 years (14‑76)</span></p> </td> </tr> <tr style="height:13.5pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="384"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33M (57%)/25F (43%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="384"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status<sup>a</sup></span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">19 (33%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">38 (66%)</span></p> </td> </tr> <tr style="height:5.65pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior ASCT</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15 (26%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Prior chemotherapy Regimens (range)</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (1‑6)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Histologically confirmed CD30‑expressing   disease</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">57 (98%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:19.6pt;text-indent:-.15in;page-break-after:   avoid"><span lang="EN-GB">Anaplastic lymphoma kinase (ALK)-negative disease</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">42 (72%)</span></p> </td> </tr> <tr style="height:15.1pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="384"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Primary Refractory to frontline therapy<sup>b</sup></span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">36 (62%)</span></p> </td> </tr> <tr style="height:7.15pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Refractory to most recent therapy</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">29 (50%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Relapsed to most recent therapy</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">29 (50%)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Baseline B symptoms</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">17 (29%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage III at initial diagnosis</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">8 (14%)</span></p> </td> </tr> <tr style="height:6.35pt"> <td style="width:288.05pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="384"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Stage IV at initial diagnosis</span></p> </td> <td style="width:161.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">21 (36%)</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">a.</span><span lang="EN-GB" style="font-size:9.0pt">One patient had a baseline ECOG status of 2, which was prohibited by protocol and is captured as Inclusion Criteria Not Met.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">b.</span><span lang="EN-GB" style="font-size:9.0pt">Primary refractory sALCL is defined as a failure to achieve a complete remission to, or progressed within 3 months of completing frontline therapy.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">The median time from initial sALCL diagnosis to first dose with ADCETRIS was 16.8 months. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Ten (10) patients (17%) received 16 cycles of </span><span lang="EN-GB" style="font-size:11.0pt">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt">; the median number of cycles received was 7 (range, 1 to 16). </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Response to treatment with </span><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> was assessed by Independent Review Facility (IRF) using the Revised Response Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data. Response assessments were performed at cycles 2, 4, 7, 10, 13 and 16 with PET at cycles 4 and 7. </span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal"><span lang="EN-GB">The ORR per IRF assessment was 86% (50 of 58 patients in the ITT set). CR was 59% (34 of 58 patients in the ITT set) and tumour reduction (of any degree) was achieved in 97% of patients. The estimated overall survival at 5 years was 60% (95% CI [47%,73%]). The median observation time (time to death or last contact) from first dose was 71.4 months. The investigator assessments were generally consistent with the independent review of the scans. Of the patients treated, 9 responding patients went on to receive an allogeneic stem cell transplant (SCT) and 9 responding patients went on to autologous SCT. For further efficacy results, see Table 16 and Figure 7.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 16: Efficacy results in relapsed or refractory sALCL patients treated with 1.8 mg/kg of </span></b><b><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> every 3 weeks<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none" width="600"> <tr style="height:15.1pt"> <td nowrap="" style="width:189.0pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Best   clinical response</span></b><b><sup></sup></b><b><span lang="EN-GB">(n = 58</span></b><sup></sup><b><span lang="EN-GB">)</span></b></p> </td> <td nowrap="" style="width:139.5pt;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">IRF n (%)</span></b></p> </td> <td nowrap="" style="width:121.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Objective response rate (CR + PR)</span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">50 (86)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">74.6, 93.9</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">            Complete remission (CR)</span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">34 (59)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">44.9, 71.4</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">            Partial remission (PR)</span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">16 (28)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">NA</span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">52 (90)</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">78.8, 96.1</span></p> </td> </tr> <tr style="height:15.1pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Duration   of response</span></b><sup></sup></p> </td> <td style="width:139.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median per IRF </span></b></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="PT-BR">      Objective response (CR + PR)<sup>a</sup></span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">13.2 </span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">5.7, 26.3 </span></p> </td> </tr> <tr style="height:12.75pt"> <td nowrap="" style="width:189.0pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">      Complete remission (CR)</span></p> </td> <td nowrap="" style="width:139.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">26.3</span></p> </td> <td nowrap="" style="width:121.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">13.2, NE<sup>b</sup></span></p> </td> </tr> <tr style="height:14.75pt"> <td style="width:189.0pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Progression   Free Survival</span></b></p> </td> <td style="width:139.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median per IRF</span></b></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:14.75pt"> <td style="width:189.0pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="252"> <p class="MsoNormal" style="text-indent:9.05pt;page-break-after:avoid"><span lang="EN-GB">Median</span></p> </td> <td style="width:139.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14.6</span></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">6.9, 20.6</span></p> </td> </tr> <tr style="height:14.75pt"> <td style="width:189.0pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="252"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Overall   survival</span></b><sup></sup></p> </td> <td style="width:139.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Median</span></b></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">95% CI</span></b></p> </td> </tr> <tr style="height:17.45pt"> <td style="width:189.0pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:17.45pt" valign="top" width="252"> <p class="MsoNormal" style="text-indent:9.0pt;page-break-after:avoid"><span lang="EN-GB">Median</span></p> </td> <td style="width:139.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:17.45pt" valign="top" width="186"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">Not reached<sup> </sup></span></p> </td> <td style="width:121.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:17.45pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">21.3, NE<sup>b</sup></span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">a.</span></sup><span lang="EN-GB" style="font-size:9.0pt">The range of DOR was 0.1 months to 39.1+ months and the median follow‑up time from first dose for patients who achieved objective response (OR) per IRF was 15.5 months. </span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><sup><span lang="EN-GB" style="font-size:11.0pt">b.</span></sup><span lang="EN-GB" style="font-size:9.0pt">Not estimable.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"><b><span style="font-size:11.0pt">Figure 7: Kaplan-Meier Plot of OS</span></b></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt"><img border="0" height="302" src="#image7" width="605"/></span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">An exploratory intra-patient analysis showed that approximately 69% of the sALCL patients treated with ADCETRIS as part of the SG035‑0004 clinical study experienced an improvement in clinical benefit as measured by longer progression free survival (PFS) compared with their most recent prior line of therapy.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt;color:black">Of the 17 patients (29%) who had B symptoms at baseline, 14 patients (82%) experienced resolution of all B symptoms in a median time from initiation of </span><span lang="EN-GB" style="font-size:11.0pt; color:black">ADCETRIS</span><span lang="EN-GB" style="font-size:11.0pt; color:black"> of 0.7 months.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study SGN35‑006 (Retreatment study)</span></p><p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">The efficacy of retreatment in patients who had previously responded (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2, open‑label, multicenter trial. Seven patients with relapsed sALCL received a starting dose of 1.8 mg/kg and one patient received a starting dose of 1.2 mg/kg of ADCETRIS administered intravenously over 30 minutes every 3 weeks. The median number of cycles was 8.5 (range, 2 to 30 cycles).</span><span lang="EN-GB" style="color:windowtext">Of the 8 sALCL patients, 3 were retreated twice for a total of 11 retreatment experiences. Retreatment with ADCETRIS resulted in 6 CRs (55%) and 4 PRs (36%), for an ORR of 91%. </span><span lang="EN-GB" style="color:windowtext">The median duration of response was 8.8 and 12.3 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Cutaneous T‑cell lymphoma</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="letter-spacing:-.1pt"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Study C25001 </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoBodyText"><span lang="EN-GB" style="font-size:11.0pt">The efficacy and safety of ADCETRIS as a single agent was evaluated in a pivotal phase 3, open-label, randomised, multicentre study in 128 patients with histologically confirmed CD30+ CTCL. </span><span style="font-size:11.0pt">CD30 positivity was defined as ≥10% target lymphoid cells demonstrating membrane, cytoplasmic, and/or Golgi staining pattern based on an immunohistochemistry assay (Ventana anti‑CD30 [Ber‑H2]). </span><span lang="EN-GB" style="font-size:11.0pt">Patients with a diagnosis of mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL] were considered eligible for the study. Patients were stratified by these disease types and randomised 1:1 to receive either ADCETRIS or the physician’s choice of either methotrexate or bexarotene. Patients with pcALCL received either prior radiation therapy or at least 1 prior systemic therapy and patients with MF received at least 1 prior systemic therapy. Patients with a concurrent diagnosis of systemic ALCL, Sezary syndrome and other non‑Hodgkin lymphoma (except for lymphomatoid papulosis [LyP]) were excluded from this study. Patients were treated with 1.8 mg/kg of ADCETRIS intravenously over 30 minutes every 3 weeks for up to 16 cycles or physician’s choice for up to 48 weeks. The median number of cycles was approximately 12 cycles in the ADCETRIS arm. In the physician’s choice arm, the median duration of treatment (number of cycles) for patients receiving bexarotene was approximately 16 weeks (5.5 cycles) and 11 weeks (3 cycles) for patients receiving methotrexate. Table 17 provides a summary of the baseline patient and disease characteristics.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 17: Summary of baseline patient and disease characteristics in the phase 3 CTCL Study (ITT Population)<br/> <br/> </span></b></p><div align="center"> <table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:455.6pt;border-collapse:collapse;border:none" width="607"> <tr style="height:15.1pt"> <td colspan="2" style="width:178.15pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="238"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:155.9pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 64</span></b></p> </td> <td style="width:121.55pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Physician’s Choice (Methotrexate or Bexarotene)</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 64</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">62 years (22‑83)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">58.5 years (22‑83)</span></p> </td> </tr> <tr style="height:13.5pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="238"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Patients ≥ 65 years old n (%)</span></p> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender n (%)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">28 (44%)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33M (52%)/31F (48%)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">24 (38%)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">37M (58%)/27F (42%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="238"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status n (%)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">43 (67)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">46 (72)</span></p> </td> </tr> <tr style="height:5.65pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18 (28)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3 (5)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">16 (25)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (3)</span></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="238"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of prior therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">4 (0‑13)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.5 (1‑15)</span></p> </td> </tr> <tr style="height:7.15pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of skin-directed therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (0‑6)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (0‑9)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of systemic therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (0‑11)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (1‑8)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:176.5pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="235"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">MF, n (%)</span></p> </td> <td colspan="2" style="width:157.55pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="210"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">48 (75)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">49 (77)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Early (IA‑IIA)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15 (31)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18 (37)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Advanced (IIB‑IVB<sup>a</sup>)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">32 (67)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">30 (61)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:176.5pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="235"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">pcALCL, n (%)</span></p> </td> <td colspan="2" style="width:157.55pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="210"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">16 (25)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">15 (23)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Skin only </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">9 (56)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11 (73)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Extracutaneous disease</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">7 (44)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">4 (27)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="235"></td> <td style="border:none" width="2"></td> <td style="border:none" width="208"></td> <td style="border:none" width="162"></td> </tr> </table> </div><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:455.6pt;border-collapse:collapse;border:none" width="607"> <tr style="height:15.1pt"> <td colspan="2" style="width:178.15pt;border:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="238"> <p class="MsoNormal" style="margin-bottom:3.0pt;page-break-after:avoid"><b><span lang="EN-GB">Patient characteristics</span></b></p> </td> <td style="width:155.9pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 64</span></b></p> </td> <td style="width:121.55pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Physician’s Choice (Methotrexate or Bexarotene)</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 64</span></b></p> </td> </tr> <tr style="height:13.5pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:3.1pt;text-indent:5.5pt;page-break-after:   avoid"><span lang="EN-GB">Median age (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">62 years (22‑83)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">58.5 years (22‑83)</span></p> </td> </tr> <tr style="height:13.5pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="238"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Patients ≥ 65 years old n (%)</span></p> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">Gender n (%)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">28 (44%)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">33M (52%)/31F (48%)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.5pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">24 (38%)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">37M (58%)/27F (42%)</span></p> </td> </tr> <tr style="height:12.75pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="238"> <p class="MsoNormal" style="text-indent:8.6pt;page-break-after:avoid"><span lang="EN-GB">ECOG status n (%)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:12.75pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">0</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">43 (67)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.75pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">46 (72)</span></p> </td> </tr> <tr style="height:5.65pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">1</span></p> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">2</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18 (28)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3 (5)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.65pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">16 (25)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (3)</span></p> </td> </tr> <tr style="height:15.1pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="238"> <p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:3.0pt;   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;   text-indent:-19.45pt;page-break-after:avoid"><b><span lang="EN-GB">Disease   characteristics</span></b></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.1pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:8.0pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of prior therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">4 (0‑13)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.0pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.5 (1‑15)</span></p> </td> </tr> <tr style="height:7.15pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of skin-directed therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (0‑6)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:7.15pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (0‑9)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">Median number of systemic therapies (range)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (0‑11)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2 (1‑8)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:176.5pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="235"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">MF, n (%)</span></p> </td> <td colspan="2" style="width:157.55pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="210"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">48 (75)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">49 (77)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Early (IA‑IIA)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15 (31)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18 (37)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Advanced (IIB‑IVB<sup>a</sup>)</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">32 (67)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">30 (61)</span></p> </td> </tr> <tr style="height:6.4pt"> <td style="width:176.5pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="235"> <p class="MsoNormal" style="margin-left:8.6pt;page-break-after:avoid"><span lang="EN-GB">pcALCL, n (%)</span></p> </td> <td colspan="2" style="width:157.55pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="210"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">16 (25)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="margin-left:-.85pt;text-align:center;   page-break-after:avoid"><span lang="EN-GB">15 (23)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Skin only </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">9 (56)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11 (73)</span></p> </td> </tr> <tr style="height:6.4pt"> <td colspan="2" style="width:178.15pt;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="238"> <p class="MsoNormal" style="margin-left:19.6pt;page-break-after:avoid"><span lang="EN-GB">Extracutaneous disease</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">7 (44)</span></p> </td> <td style="width:121.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="162"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">4 (27)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="235"></td> <td style="border:none" width="2"></td> <td style="border:none" width="208"></td> <td style="border:none" width="162"></td> </tr> </table><p class="MsoNormal"><sup><span lang="EN-GB">a</span></sup><span lang="EN-GB" style="font-size:9.0pt">One patient in each arm had incomplete staging data and are not included in the table.</span></p><p class="MsoNormal"><b></b></p><p class="MsoNormal"><span lang="EN-GB">The most common prior skin directed therapies in the ITT population were radiotherapy (64%), phototherapy (48%) and topical steroids (17%). The most common prior systemic therapies in the ITT population were chemotherapy (71%), immunotherapy (43%) and bexarotene (38%).</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The primary endpoint was objective response rate that lasts at least 4 months (ORR4) (duration from first response to last response ≥ 4 months), as determined by an independent review of the Global Response Score (GRS) consisting of skin evaluations (modified severity weighted assessment tool [mSWAT] as assessed per investigator), nodal and visceral radiographic assessment, and detection of circulating Sézary cells (Olsen 2011). Table 18 includes the results for ORR4 and other key secondary endpoints.</span></p><p class="MsoNormal"><b></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 18: Efficacy results in CTCL patients treated with 1.8 mg/kg of ADCETRIS every 3 weeks (ITT population)<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr> <td style="width:168.45pt;border:solid windowtext 1.0pt;   border-right:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"></p> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td style="width:92.1pt;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">ADCETRIS      (n = 64)</span></b></p> </td> <td style="width:87.7pt;border-top:solid windowtext 1.0pt;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="117"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td colspan="2" style="width:116.1pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">Physician’s Choice (Methotrexate or   Bexarotene) </span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n = 64</span></b></p> </td> </tr> <tr> <td colspan="5" style="width:464.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="619"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Objective   Response Rate lasting at least 4 months (ORR4) per IRF</span></b></p> </td> </tr> <tr> <td style="width:168.45pt;border:none;border-left:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">n (%)</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Percent   Difference (95% CI)</span></p> </td> <td style="width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">36 (56.3)</span></p> </td> <td colspan="2" style="width:99.25pt;border:none;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="132"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">43.8 (29.1, 58.4)</span></p> </td> <td style="width:104.55pt;border:none;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="139"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">8 (12.5)</span></p> </td> </tr> <tr> <td style="width:168.45pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">p-value</span></p> </td> <td style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td colspan="2" style="width:99.25pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="132"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">&lt;0.001</span></p> </td> <td style="width:104.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="139"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr> <td colspan="5" style="width:464.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="619"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="IT">Complete   Response (CR) per IRF</span></b></p> </td> </tr> <tr> <td style="width:168.45pt;border:none;border-left:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">n (%)</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Percent   Difference (95% CI)</span></p> </td> <td style="width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">10 (15.6)</span></p> </td> <td style="width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14.1 (-4.0, 31.5)</span></p> </td> <td colspan="2" style="width:116.1pt;border:none;   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">1 (1.6)</span></p> </td> </tr> <tr style="height:4.0pt"> <td style="width:168.45pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Adjusted   p-value<sup>a</sup></span></p> </td> <td style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.0046</span></p> </td> <td colspan="2" style="width:116.1pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:4.0pt"> <td colspan="5" style="width:464.35pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="619"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Progression   Free Survival (PFS) per IRF</span></b></p> </td> </tr> <tr style="height:4.0pt"> <td style="width:168.45pt;border:none;border-left:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Median   (months)</span></p> </td> <td style="width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">16.7</span></p> </td> <td style="width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td colspan="2" style="width:116.1pt;border:none;   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">3.5</span></p> </td> </tr> <tr style="height:4.0pt"> <td style="width:168.45pt;border:none;border-left:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Hazard   Ratio</span></p> </td> <td style="width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0.270</span></p> </td> <td colspan="2" style="width:116.1pt;border:none;   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:4.0pt"> <td style="width:168.45pt;border:none;border-left:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">95% CI</span></p> </td> <td style="width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;   height:4.0pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(0.17, 0.43)</span></p> </td> <td colspan="2" style="width:116.1pt;border:none;   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr style="height:4.0pt"> <td style="width:168.45pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="225"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Adjusted   p-value<sup>a</sup></span></p> </td> <td style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="123"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> <td style="width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="117"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">&lt;0.001</span></p> </td> <td colspan="2" style="width:116.1pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:4.0pt" valign="top" width="155"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"></p> </td> </tr> <tr height="0"> <td style="border:none" width="225"></td> <td style="border:none" width="123"></td> <td style="border:none" width="117"></td> <td style="border:none" width="15"></td> <td style="border:none" width="139"></td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"><sup><span lang="EN-GB">a</span></sup><span lang="EN-GB" style="font-size:9.0pt">   Calculated from a weighted Holm’s procedure.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Pre-specified subgroup analyses of ORR4 per IRF were performed by patients’ CTCL subtype, physicians’ choice of treatment, baseline ECOG status, age, gender, and geographic region. The analyses showed a consistent trend towards benefit for patients who received ADCETRIS compared with patients who received physician’s choice. ORR4 was 50% and 75% in the ADCETRIS arm versus 10.2% and 20% in the physician’s choice arm for MF and pcALCL, respectively.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><span lang="EN-GB">No meaningful differences in quality of life (assessed by the EuroQol five dimensions questionnaire [EQ-5D] and Functional Assessment of Cancer Therapy-General [FACT-G]) were observed between the treatment arms.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The efficacy and safety of ADCETRIS were evaluated in two additional open-label studies in 108 patients with relapsed CD30+ CTCL (including MF and pcALCL as well as SS, LyP and mixed CTCL histology), <span style="background:white">regardless of CD30 expression level. Patients</span> were treated with ADCETRIS 1.8 mg/kg intravenously over 30 minutes every 3 weeks for up to 16 cycles. The safety and efficacy results in these studies were consistent with results in Study C25001. Overall response rates for MF were 54‑66%; pcALCL, 67%; SS, 50%; LyP, 92%; and mixed CTCL histology, 82‑85%.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB" style="color:windowtext">The safety, pharmacokinetics and anti-tumour activity of ADCETRIS in 36 paediatric patients (7‑17 years of age) with r/r HL and sALCL (children aged 7‑11 years, n = 12 and adolescents aged 12 to 17 years, n = 24) were evaluated in a phase 1/2 open-label, single-agent, multicentre dose-escalation study (C25002). Phase 1 of the study assessed the safety profile (see section 4.8), determined the paediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and assessed the pharmacokinetics of ADCETRIS (see section 5.2). Phase 1 included 3 r/r HL patients treated at 1.4 mg/kg and 9 patients (7 r/r HL and 2 sALCL) treated at 1.8 mg/kg. The MTD was not reached. The RP2D was determined to be 1.8 mg/kg. Across the study, a total of 16 patients with r/r HL and 17 patients with r/r sALCL, of whom 10 were in first relapse, were treated with 1.8 mg/kg of ADCETRIS. The best overall response rate (ORR) per independent review facility (IRF) was analysed across both study phases at the RP2D. Of these 33 patients who received the RP2D, 32 were evaluable for response. The ORR was 47% in response-evaluable patients with r/r HL, 53% in patients with r/r sALCL and 60% in sALCL patients in first relapse. Eight HL patients and 9 sALCL patients went on to receive SCT following treatment with ADCETRIS. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The European Medicines Agency has deferred the obligation to submit the results of studies with </span><span lang="EN-GB">ADCETRIS</span><span lang="EN-GB"> in one or more subsets of the paediatric population in the treatment of Hodgkin lymphoma and treatment of anaplastic large cell lymphoma (see section 4.2 for information on paediatric use).</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</span></p><p class="Paragraph" style="margin-bottom:0in"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Monotherapy</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The pharmacokinetics of </span><span lang="EN-GB">brentuximab vedotin</span><span lang="EN-GB"> were evaluated in phase 1 studies and in a population pharmacokinetic analysis of data from 314 patients. In all clinical trials, brentuximab vedotin was administered as an intravenous infusion. </span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Maximum concentrations of brentuximab vedotin ADC were typically observed at the end of infusion or the sampling timepoint closest to the end of infusion. A multiexponential decline in ADC serum concentrations was observed with a terminal half-life of approximately 4 to 6 days. Exposures were approximately dose proportional. Minimal to no accumulation of ADC was observed with multiple doses at the every 3‑week schedule, consistent with the terminal half-life estimate. Typical C<sub>max</sub> and AUC of ADC after a single 1.8 mg/kg in a phase 1 study was approximately </span><span lang="EN-GB" style="font-size:11.0pt">31.98 μg/ mL and 79.41 μg/ mL x day respectively.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">MMAE is the major metabolite of brentuximab vedotin. Median C<sub>max</sub>, AUC and T<sub>max</sub> of MMAE after a single 1.8 mg/kg of the ADC in a phase 1 study was approximately 4.97 ng/ mL, 37.03 ng/ mL x day and 2.09 days respectively. MMAE exposures decreased after multiple doses of brentuximab vedotin with approximately 50% to 80% of the exposure of the first dose being observed at subsequent doses. MMAE is further metabolised mainly to an equally potent metabolite; however, its exposure is an order of magnitude lower than that of MMAE. Thus, it is not likely to have any substantial contribution to the systemic effects of MMAE.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In the first cycle, higher MMAE exposure was associated with an absolute decrease in neutrophil count.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Combination therapy</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal"><span lang="EN-GB">The pharmacokinetics of ADCETRIS in combination with AVD were evaluated in a single phase 3 study in 661 patients. Population pharmacokinetic analysis indicated that the pharmacokinetics of ADCETRIS in combination with AVD were consistent to that in monotherapy. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">After multiple‑dose, IV infusion of 1.2 mg/kg brentuximab vedotin every two weeks, maximal serum concentrations of ADC were observed near the end of the infusion and elimination exhibited a multi‑exponential decline with a t<sub>1/2z</sub> of approximately 4 to 5 days. Maximal plasma concentrations of MMAE were observed approximately 2 days after the end of infusion, and exhibited a mono‑exponential decline with a t<sub>1/2z </sub>of approximately 3 to 4 days.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">After multiple‑dose, IV infusion of 1.2 mg/kg brentuximab vedotin every two weeks, steady‑state trough concentrations of ADC and MMAE were achieved by Cycle 3. Once steady-state was achieved, the PK of ADC did not appear to change with time. ADC accumulation (as assessed by AUC<sub>14D</sub> between Cycle 1 and Cycle 3) was 1.27‑fold. The exposure of MMAE (as assessed by AUC<sub>14D</sub> between Cycle 1 and Cycle 3) appeared to decrease with time by approximately 50%.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The pharmacokinetics of ADCETRIS in combination with CHP were evaluated in a single phase 3 study in 223 patients (SGN35‑014). After multiple-dose IV infusion of 1.8 mg/kg ADCETRIS every 3 weeks, the pharmacokinetics of ADC and MMAE were similar to those of monotherapy.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><i><span lang="EN-GB" style="font-size:11.0pt">In vitro</span></i><span lang="EN-GB" style="font-size: 11.0pt">, </span><span lang="EN-GB" style="font-size:11.0pt">the binding of MMAE to human serum plasma proteins ranged from 68‑82%. MMAE is not likely to displace or to be displaced by highly protein-bound medicines. <i>In vitro</i>, MMAE was a substrate of P‑gp and was not an inhibitor of P‑gp at clinical concentrations.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">In humans, the mean steady state volume of distribution was approximately 6‑10 L for ADC. Based on population PK estimation the typical apparent central volume of distribution of MMAE was 35.5 L.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism</span></u></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The ADC is expected to be catabolised as a protein with component amino acids recycled or eliminated.</span></p><p class="Paragraph" style="margin-bottom:0in"></p><p class="MsoNormal" style="margin-right:-.1pt"><i><span lang="EN-GB">In</span></i><span lang="EN-GB"> <i>vivo</i> data in animals and humans suggest that only a small fraction of MMAE released from </span><span lang="EN-GB">brentuximab vedotin is metabolised. The levels of MMAE metabolites have not been measured in human plasma. At least one metabolite of MMAE has been shown to be active <i>in vitro.</i> </span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">MMAE is a substrate of CYP3A4 and possibly CYP2D6. <i>In vitro</i> data indicate that the MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. <i>In vitro</i> studies using human liver microsomes indicate that MMAE inhibits only CYP3A4/5 at concentrations much higher than was achieved during clinical application. MMAE does not inhibit other isoforms. </span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">MMAE did not induce any major CYP450 enzymes in primary cultures of human hepatocytes.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The ADC is eliminated by catabolism with a typical estimated CL and half life of 1.5 L/day and 4‑6 days respectively. </span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The elimination of MMAE was limited by its rate of release from ADC, typical apparent CL and half life of MMAE was 19.99 L/day and 3‑4 days respectively. </span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">An excretion study was undertaken in patients who received a dose of 1.8 mg/kg of brentuximab vedotin. Approximately 24% of the total MMAE administered as part of the ADC during a brentuximab vedotin infusion was recovered in both urine and faeces over a 1‑week period. Of the recovered MMAE, approximately 72% was recovered in the faeces. A lesser amount of MMAE (28%) was excreted in the urine.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Pharmacokinetics in special populations</span></u></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Population PK analysis showed that baseline serum albumin concentration was a significant covariate of MMAE clearance. The analysis indicated that MMAE clearance was 2‑fold lower in patients with low serum albumin concentrations &lt;3.0 g/dL compared with patients with serum albumin concentrations within the normal range.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">A study evaluated the PK of brentuximab vedotin and MMAE after the administration of 1.2 mg/kg of ADCETRIS to patients with mild (Child-Pugh A; n = 1), moderate (Child-Pugh B; n = 5) and severe (Child-Pugh C; n = 1) hepatic impairment. Compared to patients with normal hepatic function, MMAE exposure increased approximately 2.3‑fold (90% CI 1.27‑4.12‑fold) in patients with hepatic impairment.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">A study evaluated the PK of brentuximab vedotin and MMAE after the administration of 1.2 mg/kg of ADCETRIS to patients with mild (n = 4), moderate (n = 3) and severe (n = 3) renal impairment. Compared to patients with normal renal function, MMAE exposure increased approximately 1.9‑fold (90% CI 0.85‑4.21‑fold) in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). No effect was observed in patients with mild or moderate renal impairment.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Elderly</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The population pharmacokinetics of brentuximab vedotin were examined from several studies, including data from 380 patients up to 87 years old (34 patients </span><span lang="EN-GB">≥65‑&lt; 75 and 17 patients ≥75 years of age</span><span lang="EN-GB">). Additionally, the population pharmacokinetics of brentuximab vedotin in combination with AVD were examined, including data from 661 patients up to 82 years old (</span><span lang="EN-GB">42 patients ≥ 65‑&lt; 75 and 17 patients ≥ 75 years of age). The influence of age on pharmacokinetics was investigated in each analysis and it was not a significant covariate.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph"><u><span lang="EN-GB" style="background:yellow"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The pharmacokinetics of brentuximab vedotin ADC and MMAE following a 30‑minute intravenous infusion of BV administered at 1.4 mg/kg or 1.8 mg/kg given every 3 weeks were evaluated in a phase 1/2 clinical trial of 36 paediatric patients (7‑17 years of age) with r/r HL and sALCL (children aged 7‑11 years, n = 12 and adolescents aged 12 to 17 years, n = 24) (see section 5.1). The C<sub>max</sub> of ADC was typically observed at the end of infusion or the sampling closest to the end of infusion. A multi-exponential decline in ADC serum concentrations was observed with a terminal half-life of approximately 4 to 5 days. Exposures were approximately dose proportional with a trend observed for lower ADC exposures at lower ages/ body weights in the study population. </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Median ADC AUC in children and adolescents from this study was approx. 14% and 3% lower than in adult patients, respectively, while MMAE exposures were 53% lower and 13% higher, respectively, than in adult patients.</span><span lang="EN-GB" style="color:windowtext"> Median C<sub>max</sub> and AUC of ADC after a single 1.8 mg/kg dose were 29.8 µg/ mL and 67.9 µg*day/ mL, respectively, in patients &lt; 12 years of age and 34.4 µg/mL and 77.8 µg*day/mL, respectively, in patients ≥ 12 years of age. Median C<sub>max</sub>, AUC, and T<sub>max</sub> of MMAE after a single 1.8 mg/kg dose were 3.73 ng/mL, 17.3 ng*day/mL, and 1.92 days, respectively, in patients &lt; 12 years of age and 6.33 ng/mL, 42.3 ng*day/mL, and 1.82 days, respectively, in patients ≥ 12 years of age. </span><span lang="EN-GB" style="color:windowtext">There was a trend of increased clearance of brentuximab vedotin in paediatric patients confirmed positive for ADAs. No patients aged &lt; 12 years (0 of 11) and 2 patients aged ≥ 12 years (2 of 23) became persistently ADA positive.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="Paragraph" style="margin-bottom:0in;page-break-after:avoid"></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">MMAE has been shown to have aneugenic properties in an <i>in vivo</i> rat bone marrow micronucleus study. These results were consistent with the pharmacological effect of MMAE on the mitotic apparatus (disruption of the microtubule network) in cells.</span></p><p class="Default"></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">The effects of </span><span lang="EN-GB" style="font-size:11.0pt">brentuximab vedotin on human male and female fertility have not been studied. However, results of repeat-dose toxicity studies in rats indicate the potential for brentuximab vedotin to impair male reproductive function and fertility. Testicular atrophy and degeneration were partially reversible following a 16‑week treatment-free period.</span></p><p class="Default"></p><p class="MsoListBullet" style="margin-left:0in;text-indent:0in"><span lang="EN-GB" style="font-size:11.0pt">Brentuximab vedotin caused embryo-foetal lethality in pregnant female rats. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">In nonclinical studies, lymphoid depletion and reduced thymic weight were observed, consistent with the pharmacologic disruption of microtubules caused by MMAE derived from brentuximab vedotin.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB" style="color:windowtext">Citric acid monohydrate </span><span style="color:windowtext">(for pH-adjustment)</span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB" style="color:windowtext">Sodium citrate dihydrate </span><span style="color:windowtext">(for pH-adjustment)</span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="EN-GB">α,α‑Trehalose dihydrate</span></p><p class="MsoNormal"><span lang="EN-GB">Polysorbate 80</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">4 years.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">After reconstitution/dilution, from a microbiological point of view, the product should be used immediately. However, chemical and physical in‑use stability has been demonstrated for 24 hours at 2 </span><span lang="EN-GB">°</span><span lang="EN-GB">C‑8 </span><span lang="EN-GB">°</span><span lang="EN-GB">C.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Store in a refrigerator (2 °C‑8 °C). </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Do not freeze. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Keep the vial in the original carton in order to protect from light.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</span></p><p class="MsoNormal" style="text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Type I glass vial with a butyl rubber stopper and an aluminium/plastic flip-off seal, containing 50 mg powder.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Pack of 1 vial. </span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="Default" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">General precautions</span></u></p><p class="Default" style="page-break-after:avoid"></p><p class="Paragraph" style="margin-bottom:0in"><span lang="EN-GB" style="font-size: 11.0pt">Procedures for proper handling and disposal of anticancer medicinal products should be considered. </span></p><p class="Default"></p><p class="Default"><span lang="EN-GB" style="font-size:11.0pt">Proper aseptic technique throughout the handling of this medicinal product should be followed.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Instructions for reconstitution </span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Each single use vial must be reconstituted with 10.5 mL of water for injections to a final concentration of 5 mg/ mL. Each vial contains a 10% overfill giving 55 mg of ADCETRIS per vial and a total reconstituted volume of 11 mL.</span></p><p class="MsoNormal"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">1.</span><span lang="EN-GB">Direct the stream toward the wall of the vial and not directly at the cake or powder. </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB">2.</span><span lang="EN-GB">Gently swirl the vial to aid dissolution. DO NOT SHAKE.</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB">3.</span><span lang="EN-GB">The reconstituted solution in the vial is a clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">4.</span><span lang="EN-GB">The reconstituted solution should be inspected visually for any foreign particulate matter and/or discolouration. In the event of either being observed, discard the medicinal product. </span></p><p class="Default"><u><span lang="EN-GB" style="font-size:11.0pt"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Preparation of infusion solution</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The appropriate amount of reconstituted ADCETRIS must be withdrawn from the vial(s) and added to an infusion bag containing sodium chloride 9 mg/ mL (0.9%) solution for injection in order to achieve a final concentration of 0.4‑1.2 mg/ mL ADCETRIS. The recommended diluent volume is 150 mL. The already reconstituted ADCETRIS can also be diluted into 5% dextrose for injection or Lactated Ringer's for injection. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Gently invert the bag to mix the solution containing ADCETRIS. DO NOT SHAKE. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Any portion left in the vial, after withdrawal of the volume to be diluted, must be disposed of in accordance with local requirements. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not add other medicinal products to the prepared ADCETRIS infusion solution or intravenous infusion set. The infusion line should be flushed following administration with sodium chloride 9 mg/ mL (0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's for injection. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Following dilution, infuse the ADCETRIS solution immediately at the recommended infusion rate. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Total storage time of the solution from reconstitution to infusion should not exceed 24 hours. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Determining dosage amount:</span></u></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Calculation to determine the total ADCETRIS dose (mL) to be further diluted (see section 4.2): </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:496.15pt;margin-left:5.4pt;border-collapse:collapse" width="662"> <tr> <td style="width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="340"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">ADCETRIS   dose (mg/kg) x patient’s body weight (kg)</span></p> </td> <td rowspan="2" style="width:241.0pt;padding:0in 5.4pt 0in 5.4pt" width="321"> <p class="MsoNormal"><span lang="EN-GB"> = Total ADCETRIS   dose (mL) to be further diluted</span></p> </td> </tr> <tr> <td style="width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt" width="340"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">Reconstituted   vial concentration (5 mg/mL)</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Note: If patient’s weight is more than 100 kg, the dose calculation should use 100 kg. The maximal recommended dose is 180 mg. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Calculation to determine the total number of ADCETRIS vials needed: </span></i></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in;page-break-after: avoid"></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:496.15pt;margin-left:5.4pt;border-collapse:collapse" width="662"> <tr> <td style="width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="340"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">Total   ADCETRIS dose (mL) to be administered</span></p> </td> <td rowspan="2" style="width:241.0pt;padding:0in 5.4pt 0in 5.4pt" width="321"> <p class="MsoNormal"><span lang="EN-GB"> = Number of ADCETRIS vials   needed</span></p> </td> </tr> <tr> <td style="width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt" width="340"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">Total   volume per vial (10 mL/vial)</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table 19: Sample calculations for patients receiving the recommended dose of 1.8 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none"> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Patient   weight (kg)</span></b></p> </td> <td style="width:126.45pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Total   dose = </span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">patient   weight multiplied by recommended dose [1.8 mg/kg<sup>a</sup>])</span></b></p> </td> <td style="width:148.8pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Total   volume to be diluted<sup>b</sup> = total dose divided by reconstituted   vial concentration [5 mg/ mL])</span></b></p> </td> <td style="width:136.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Number   of vials needed = </span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">total   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">60 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">108 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">21.6 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2.16 vials</span></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">80 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">144 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28.8 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2.88 vials</span></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">100 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">180 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">36 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">3.6 vials</span></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">120 kg<sup>c</sup></span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">180 mg<sup>   d</sup></span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">36 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">3.6 vials</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">a.</span><span lang="EN-GB" style="font-size:9.0pt">For a reduced dose, use 1.2 mg/kg for the calculation.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">b.</span><span lang="EN-GB" style="font-size:9.0pt">To be diluted in 150 mL of diluent and administered by intravenous infusion over 30 minutes every 3 weeks.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">c.</span><span lang="EN-GB" style="font-size:9.0pt">If patient’s weight is more than 100 kg, the dose calculation should use 100 kg.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in"><span lang="EN-GB" style="font-size:8.0pt">d.</span><span lang="EN-GB" style="font-size:9.0pt">The maximal recommended dose is 180 mg.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:4.5pt;page-break-after:avoid"><b><span lang="EN-GB">Table 20: Sample calculations for patients receiving the recommended dose of 1.2 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg as combination therapy or when a reduced dose is required<br/> <br/> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none"> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Patient   weight (kg)</span></b></p> </td> <td style="width:126.45pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Total   dose = </span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">patient   weight multiplied by recommended dose [1.2 mg/kg<sup>a</sup>])</span></b></p> </td> <td style="width:148.8pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Total   volume to be diluted<sup>b</sup> = total dose divided by reconstituted   vial concentration [5 mg/mL])</span></b></p> </td> <td style="width:136.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Number   of vials needed = </span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">total   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">60 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">72 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">14.4 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">1.44 vials</span></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">80 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">96 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">19.2 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">1.92 vials</span></p> </td> </tr> <tr style="height:20.4pt"> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">100 kg</span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:20.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">120 mg</span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:20.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">24 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:20.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2.4 vials</span></p> </td> </tr> <tr> <td style="width:44.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="59"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">120 kg<sup>c</sup></span></p> </td> <td style="width:126.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="169"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">120 mg<sup>   d</sup></span></p> </td> <td style="width:148.8pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="198"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">24 mL</span></p> </td> <td style="width:136.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="183"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">2.4 vials</span></p> </td> </tr> </table><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">a.</span><span lang="EN-GB" style="font-size:9.0pt">For a reduced dose, use 0.9 mg/kg for the calculation.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">b.</span><span lang="EN-GB" style="font-size:9.0pt">To be diluted in 150 mL of diluent and administered by intravenous infusion over 30 minutes every 2 weeks as combination therapy or every 3 weeks when a reduced dose of the monotherapy is required.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">c.</span><span lang="EN-GB" style="font-size:9.0pt">If patient’s weight is more than 100 kg, the dose calculation should use 100 kg.</span></p><p class="Paragraph" style="margin-top:0in;margin-right:0in;margin-bottom:0in; margin-left:.25in;text-indent:-.25in;page-break-after:avoid"><span lang="EN-GB" style="font-size:8.0pt">d.</span><span lang="EN-GB" style="font-size:9.0pt">The maximal recommended dose for combination therapy is 120 mg.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Disposal</span></u></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS is for single use only. </span></p><p class="MsoNormal"><span lang="EN-GB">Any unused product or waste material should be disposed of in accordance with local requirements.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.   MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Takeda Pharma A/S</span></p><p class="MsoNormal"><span lang="DA">Dybendal Alle 10</span></p><p class="MsoNormal"><span lang="DA">2630 Taastrup</span></p><p class="MsoNormal"><span lang="DA">Denmark </span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.   MARKETING AUTHORISATION NUMBER "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="DA">EU/1/12/794/001</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.   DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Date of first authorisation: 25 October 2012</span></p><p class="MsoNormal"><span lang="EN-GB">Date of latest renewal: 19 September 2019</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10. DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="No-numheading3Agency" style="margin:0in;text-align:center"><span lang="EN-GB" style='font-family:"Times New Roman",serif;text-transform:uppercase'>Annex II</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB">A.      MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND <span style="text-transform:uppercase">manufacturerS responsible for batch release </span></span></b></p><p class="MsoNormal"></p><p class="MsoNormal"><b><span lang="EN-GB" style="text-transform:uppercase">B.      Conditions or restrictions regarding supply and use</span></b></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="text-transform:uppercase">C.      Other conditions and requirements of the marketing authorisation</span></b></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="text-transform:uppercase">D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="text-transform:uppercase">E.      SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION</span></b></p><p class="MsoNormal"></p><p class="NormalAgency"></p><p class="NormalAgency"></p><p class="TitleB" style="page-break-before:always"><span lang="EN-GB">A.      MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="MsoNormal"><u><span lang="EN-GB">Name and address of the manufacturers of the biological active substance </span></u></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Piramal Healthcare UK Ltd.</span></p><p class="MsoNormal"><span lang="EN-GB">Earls Road, Grangemouth</span></p><p class="MsoNormal"><span lang="EN-GB">Stirlingshire, Scotland FK3 8XG</span></p><p class="MsoNormal"><span lang="EN-GB">United Kingdom</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Lonza AG</span></p><p class="MsoNormal"><span lang="EN-GB">Lonzastrasse</span></p><p class="MsoNormal"><span lang="EN-GB">3930 Visp</span></p><p class="MsoNormal"><span lang="EN-GB">Switzerland</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><u><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name and address of the manufacturers responsible for batch release</span></u></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="MsoNormal"><span lang="EN-GB">Takeda Austria GmbH</span></p><p class="MsoNormal"><span lang="EN-GB">St. Peter‑Straβe 25</span></p><p class="MsoNormal"><span lang="PT">A‑4020 Linz</span></p><p class="MsoNormal"><span lang="PT">Austria</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="PT">Delpharm Novara S.r.l.</span></p><p class="MsoNormal">Via Crosa, 86</p><p class="MsoNormal"><span lang="EN-GB">28065 Cerano (NO)</span></p><p class="MsoNormal"><span lang="EN-GB">Italy</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.</span></p><p class="NormalAgency"></p><p class="NormalAgency"></p><p class="TitleB"><span lang="EN-GB">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="NormalAgency"></p><p class="TitleB"><span lang="EN-GB">C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt; text-autospace:none"><span lang="EN-GB" style="font-family:Symbol">·</span><b><span lang="EN-GB">Periodic safety update reports (PSURs) </span></b></p><p class="MsoListParagraphCxSpLast" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"></p><p class="TitleB"><span lang="EN-GB">D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p><p class="DraftingNotesAgency" style="margin-bottom:0in;line-height:normal"></p><p class="MsoListParagraph" style="margin-left:28.35pt;text-indent:-28.35pt; text-autospace:none"><span lang="EN-GB" style="font-family:Symbol">·</span><b><span lang="EN-GB">Risk management plan (RMP)</span></b></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.</span></p><p class="NormalAgency"></p><p class="NormalAgency" style="page-break-after:avoid"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>An updated RMP should be submitted:</span></p><p class="NormalAgency" style="margin-left:27.5pt;text-indent:-27.5pt"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol">·</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>At the request of the European Medicines Agency; </span></p><p class="NormalAgency" style="margin-left:27.5pt;text-indent:-27.5pt"><span lang="EN-GB" style="font-size:11.0pt;font-family:Symbol">·</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached</span></p><p class="NormalAgency"></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><p class="TitleB" style="page-break-after:avoid"><span lang="EN-GB">E.      <span style="text-transform:uppercase">Specific Obligation to complete post-authorisation measures for the conditional marketing authorisation</span> </span></p><p class="NormalAgency" style="page-break-after:avoid"></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>This being a conditional marketing authorisation and pursuant to Article 14a(4) of Regulation (EC) No<span style="layout-grid-mode:line"> 726/2004, the MAH shall complete, within the stated timeframe, the following measure:</span></span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none" width="98%"> <thead> <tr> <td style="width:55.38%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="55%"> <p class="MsoNormal" style="margin-right:-.05pt"><b><span lang="EN-GB">Description</span></b></p> </td> <td style="width:44.62%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="44%"> <p class="MsoNormal" style="margin-right:-.05pt"><b><span lang="EN-GB">Due date</span></b></p> </td> </tr> </thead> <tr> <td style="width:55.38%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="55%"> <p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif;   color:black'>To perform a single‑arm study in a similar patient   population as the sALCL population investigating response rate, duration of   response, rate of (second) ASCT and data in subpopulations (including but not   necessarily restricted to ALK status and age) based on a CHMP agreed protocol   (Study C25006).</span></p> </td> <td style="width:44.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="44%"> <p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"></p> <p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif;   color:black'>Final Study Report by: Q4 2021</span></p> </td> </tr> </table><p class="MsoNormal"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><h1><span lang="EN-GB">ANNEX III</span></h1><p align="center" class="MsoNormal" style="text-align:center"></p><h1><span lang="EN-GB">LABELLING AND PACKAGE LEAFLET</span></h1><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p class="TitleA"><span lang="EN-GB">A. LABELLING</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS 50 mg powder for concentrate for solution for infusion</span></p><p class="MsoNormal"><span lang="EN-GB">brentuximab vedotin</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Each vial contains 50 mg of brentuximab vedotin</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">After reconstitution each vial contains 5 mg/ml of brentuximab vedotin</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="3.       LIST OF EXCIPIENTS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Excipients: Ci</span><span lang="EN-GB">tric acid monohydrate</span><span lang="EN-GB">, s</span><span lang="EN-GB">odium citrate dihydrate</span><span lang="EN-GB">, </span><span lang="EN-GB">α,α‑</span><span lang="EN-GB">t</span><span lang="EN-GB">rehalose dihydrate,</span><span lang="EN-GB"> p</span><span lang="EN-GB">olysorbate 80</span></p><p class="MsoNormal"><span lang="EN-GB" style="background:silver">See package leaflet for further information</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="background:silver">Powder for concentrate for solution for infusion</span></i></p><p class="MsoNormal"><span lang="EN-GB">1 vial</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For intravenous use after reconstitution and dilution </span></p><p class="MsoNormal"><span lang="EN-GB">Read the package leaflet</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Keep out of the sight and reach of children</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">EXP</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Store in a refrigerator </span></p><p class="MsoNormal"><span lang="EN-GB">Do not freeze</span></p><p class="MsoNormal"><span lang="EN-GB">Keep the vial in the outer carton in order to protect from light.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For single use only</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="PT">Takeda Pharma A/S</span></p><p class="MsoNormal"><span lang="PT">Dybendal Alle 10</span></p><p class="MsoNormal"><span lang="EN-GB">2630 Taastrup</span></p><p class="MsoNormal"><span lang="EN-GB">Denmark </span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="12.    MARKETING AUTHORISATION NUMBER(S) "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">EU/1/12/794/001</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">13.    BATCH NUMBER</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Lot</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">14.    GENERAL CLASSIFICATION FOR SUPPLY</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Medicinal product subject to medical prescription</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">15.    INSTRUCTIONS ON USE</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">16.    INFORMATION IN BRAILLE</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="background:silver">Justification for not including Braille accepted</span></i></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt"> <p class="MsoNormal" style="border:none;padding:0in"><b><span lang="EN-GB">17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="background:silver">2D barcode carrying the unique identifier included.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt"> <p class="MsoNormal" style="border:none;padding:0in"><b><span lang="EN-GB">18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">PC: </span></p><p class="MsoNormal"><span lang="EN-GB">SN: </span></p><p class="MsoNormal"><span lang="EN-GB">NN:</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"></p> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">VIAL LABEL</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">1.      NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">ADCETRIS 50 mg powder for concentrate for solution for infusion</span></p><p class="MsoNormal"><span lang="EN-GB">brentuximab vedotin</span></p><p class="MsoNormal"><span lang="EN-GB" style="background:silver">IV use</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">2.      METHOD OF ADMINISTRATION</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For intravenous use after reconstitution and dilution </span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">3.      EXPIRY DATE</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">EXP</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">4.      BATCH NUMBER</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Lot</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">5.      CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">50 mg</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="MsoNormal" style="margin-left:27.0pt;text-indent:-27.0pt;border:none; padding:0in"><b><span lang="EN-GB">6.      OTHER</span></b></p> </div><p class="MsoNormal"></p><p class="MsoNormal"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"></p><p class="TitleA"><span lang="EN-GB">B. PACKAGE LEAFLET</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Package leaflet: Information for the patient</span></b></p><p align="center" class="MsoNormal" style="text-align:center"></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">Adcetris 50 mg powder for concentrate for solution for infusion</span></b></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB">brentuximab vedotin</span></b></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB"><img alt="Description: Description: Description: BT_1000x858px" border="0" height="18" id="Picture 2" src="#image8" width="21"/></span><span lang="EN-GB">This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Read all of this leaflet carefully before you start using this medicine because it contains important information for you.</span></b></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt; page-break-after:avoid"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">Keep this leaflet. You may need to read it again.</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt;page-break-after:avoid"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">If you have any further questions, ask your doctor.</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt;page-break-after:avoid"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">If you get any side effects, talk to your doctor. This includes any possible side effects not listed</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:0in;page-break-after:avoid"><span lang="EN-GB">           in this leaflet. See section 4.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">What is in this leaflet</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">1.       What Adcetris is and what it is used for</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">2.       What you need to know before you are given Adcetris</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">3.       How Adcetris will be given</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">4.       Possible side effects</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">5.       How to store Adcetris</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">6.       Contents of the pack and other information</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">1.       What Adcetris is and what it is used for</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris contains the active substance <b>brentuximab vedotin</b>, an anti-cancer agent, which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells. This substance is delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is a protein which recognises certain cancer cells. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Hodgkin lymphoma, systemic anaplastic large cell lymphoma and cutaneous T‑cell lymphoma are types of cancer of the white blood cells.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Classical Hodgkin lymphoma expresses specific proteins on the cell surface that are different from non-classical Hodgkin lymphoma. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is used to treat patients with advanced classical Hodgkin lymphoma who have not had treatment before.</span><span lang="EN-GB"> Adcetris will be given to you together with doxorubicin, vinblastine and dacarbazine which are other chemotherapy medicines used to treat Hodgkin lymphoma. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is used alone to lower the likelihood of classical Hodgkin lymphoma coming back after an autologous stem cell transplant in patients with certain risk factors.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is also used alone to treat classical Hodgkin lymphoma that has:</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">come back after or not responded to an infusion of your own healthy stem cells into your body (autologous stem cell transplant), or</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">come back after or never responded to at least two previous therapies, and where you cannot receive additional combination anti-cancer treatments or have an autologous stem cell transplant.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Systemic anaplastic large cell lymphoma is a type of non‑Hodgkin lymphoma found in your lymph nodes and/or throughout other parts of your body.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is used to treat patients with systemic anaplastic large cell lymphoma who have not had treatment before.</span><span lang="EN-GB"> Adcetris will be given to you together with </span><span lang="EN-GB">cyclophosphamide, doxorubicin and prednisone</span><span lang="EN-GB"> which are other chemotherapy medicines used to treat these conditions.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is also used to treat systemic anaplastic large cell lymphoma that has:</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">not responded to other types of anti-cancer treatments, or </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">come back after previous anti-cancer treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span style="color:windowtext">Cutaneous T‑cell lymphoma is a cancer of a certain type of white blood cell called a ‘T‑cell’ that mainly affects the skin. </span><span lang="EN-GB" style="color:windowtext">Adcetris is used to treat cutaneous T‑cell lymphoma where a specific type of protein is present on the cells’ surface.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Adcetris is used to treat cutaneous T‑cell lymphoma in patients who have previously received at least one anti-cancer medicine that travels through the bloodstream.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:17.65pt"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">2.       What you need to know before you are given Adcetris</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Do NOT use Adcetris if you</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">are allergic to brentuximab vedotin or any of the other ingredients of this medicine (listed in section 6). </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">are currently using bleomycin, an anti-cancer agent. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Warnings and precautions</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">When you first receive this medicine and during the course of treatment, tell your doctor if you:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have confusion, trouble thinking, memory loss, blurred or loss of vision, decreased strength, decreased control or sensation in one arm or leg, a change in the way of walking, or loss of balance, as these may be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you have these symptoms prior to treatment with this medicine, tell your doctor immediately about any changes in these symptoms. You should also inform your partner or caregivers about your treatment, since they may notice symptoms that you are not aware of</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have severe and persistent stomach pain, with or without nausea and vomiting, as these may be symptoms of a serious and potentially fatal condition known as pancreatitis (inflammation of the pancreas)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have new or worsening shortness of breath or cough as these may be symptoms of a serious and potentially fatal lung complication (pulmonary toxicity)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">are taking, or have previously taken, medicines which may affect your immune system, such as chemotherapy or immunosuppressive agents </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have, or think you have, an infection. Some infections may be serious and can be due to viruses, bacteria, or other causes that may be life-threatening</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">experience a whistling sound during breathing (wheezing)/difficulty breathing, hives, itching, or swelling (signs of an infusion reaction). For more detailed information, see “Infusion reactions” in section 4</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have any problems with a change in the sensitivity of the skin, especially in the hands or feet, such as numbness, tingling, a burning sensation, pain, discomfort or weakness (neuropathy)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have headaches, feel tired, experience dizziness, look pale (anaemia), or have unusual bleeding or bruising under the skin, longer than usual bleeding after your blood has been drawn, or bleeding from your gums (thrombocytopenia) </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">develop chills or shivering, or feel warm; you should take your temperature as you may have a fever. A fever with a low white blood cell count may be a sign of serious infection </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances (this may be a potentially life-threatening complication known as tumour lysis syndrome)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">experience flu-like symptoms followed by a painful red or purplish rash that spreads and blisters including extensive detachment of the skin that may be life-threatening (this may be a serious skin reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have new or worsening stomach pain, nausea, vomiting, constipation as these may be symptoms of a serious and potentially fatal stomach or intestinal complication (gastrointestinal complications)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have abnormal liver test results as this may be related to a serious and potentially fatal liver injury (hepatotoxicity). Liver disease and other medical conditions that may have been present before you start taking Adcetris and some medications that you are currently taking might increase the risk of liver injury</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">feel tired, have frequent urination, increased thirst, increased appetite with unintended weight loss, or irritability (hyperglycaemia)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">have kidney or liver problems</span></p><p class="MsoListParagraph" style="margin-left:31.5pt"></p><p class="MsoNormal"><span lang="EN-GB">Your doctor will perform regular blood tests to make sure that it is safe for you to receive this medicine.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Other medicines and Adcetris</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Tell your doctor if you are taking any other medicines, if you have taken any recently, or if you start taking new ones. This includes herbal medicines and other medicines you can obtain without a prescription. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Pregnancy, breast‑feeding and fertility</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">You and your partner must use two methods of effective contraception during your treatment with this medicine. Women must continue using contraception for 6 months following the last dose of Adcetris.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">You should not use this medicine if you are pregnant unless you and your doctor decide that the benefit to you outweighs the potential risk to the unborn baby. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">It is important to tell your doctor before and during treatment if you are pregnant, think you may be pregnant, or are planning to get pregnant.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If you are breast‑feeding, you should discuss with your doctor whether you should receive this medicine.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Men being treated with this medicine are advised to have sperm samples frozen and stored before treatment. Men are advised not to father a child during treatment with this medicine and for up to 6 months following the last dose of this medicine. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Driving and using machines</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Your treatment may influence your ability to drive or operate machines. If you feel unwell during treatment then do not drive or operate machines.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Adcetris contains sodium</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">This medicine contains 13.2 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 0.7% of the recommended maximum daily dietary intake of sodium for an adult</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">3.       How Adcetris will be given</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">If you have any questions on the use of this medicine, ask the doctor or nurse who is giving you the infusion. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Dose and frequency</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">The dose of this medicine depends on your body weight. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;text-autospace: none"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">The usual dose of Adcetris given in combination with </span><span lang="EN-GB">doxorubicin, vinblastine and dacarbazine</span><span lang="EN-GB"> is </span><span lang="EN-GB">1.2 mg/kg given every 2 weeks for 6 months. </span></p><p class="MsoNormal" style="margin-left:.25in;text-autospace:none"></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;text-autospace: none"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">The usual dose of Adcetris given in combination with cyclophosphamide, doxorubicin and prednisone is </span><span lang="EN-GB">1.8 mg/kg given every 3 weeks for approximately 4‑6 months.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">See the package leaflets for these medicines given in combination with Adcetris for additional information on their use and effects. After the first dose of Adcetris in combination with chemotherapy, your doctor may also give you a medicine that will help prevent development or reduce the severity of neutropenia (decrease of white blood cell count) which can increase the risk of infection. Tell your doctor </span><span lang="EN-GB">if you have kidney or liver problems as your doctor may lower your starting dose or may not recommend Adcetris.</span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;text-autospace: none"><span lang="EN-GB" style="font-family:Symbol">·</span><span lang="EN-GB">The usual dose of Adcetris given alone is 1.8 mg/kg, given once every 3 weeks for no more than one year. Your doctor may lower your starting dose to 1.2 mg/kg if you have kidney or liver problems.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is to be given to adults only. It is not for use in children. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">How Adcetris is given</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">This medicine is given to you into a vein (intravenously) as an infusion. It is given by your doctor or nurse over 30 minutes. Your doctor or nurse will also monitor you during and after the infusion. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If you have any other questions on the use of this medicine, ask your doctor.</span></p><p class="MsoNormal" style="margin-right:17.65pt"></p><p class="MsoNormal" style="margin-right:17.65pt"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">4.       Possible side effects </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Like all medicines, this medicine may cause side effects, although not everybody gets them. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Infusion reactions</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Medicines of this type (monoclonal antibodies) can cause infusion reactions such as:</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">a rash </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">shortness of breath</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">difficulty breathing</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">cough</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">a tight chest </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">fever</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">back pain</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt;page-break-after:avoid"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">chills</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt;page-break-after:avoid"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">headache</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">feeling sick (nausea) or being sick (vomiting).</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Infusion reactions to this medicine may affect more than 1 in 10 people. </span></p><p class="MsoDate" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">In general, these types of reactions occur within minutes to several hours following completion of the infusion. However, they may develop more than several hours after completion of the infusion but this is uncommon. These infusion reactions can be serious or even fatal (known as an anaphylactic reaction). It is not known how frequently infusion-related reactions to this medicine are serious or fatal. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">You may be given other medicines such as </span></p><p class="MsoListParagraph" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">anti-histamines, corticosteroids or paracetamol </span></p><p class="MsoNormal"><span lang="EN-GB">to help reduce any of the reactions above if you have already experienced these when receiving this type of medicine. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">If you think you have previously had a similar reaction, tell your doctor BEFORE you are given this medicine. </span></p><p class="MsoNormal"><span lang="EN-GB">If you develop infusion reactions (as stated previously), your doctor may stop giving this medicine and start support treatment.</span></p><p class="MsoNormal"><span lang="EN-GB">If your infusion is restarted, your doctor may increase the time over which your infusion is given so that you may be able to tolerate it better. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Tell your doctor straight away if you notice any of the following symptoms because some of them may be signs of a serious or possibly fatal condition:</span></b></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">progressive multifocal leukoencephalopathy (PML) symptoms such as confusion, trouble thinking, memory loss, blurred or loss of vision, decreased strength, decreased control or sensation in one arm or leg, a change in the way of walking, or loss of balance (for more detailed information, see section 2) (affects less than 1 in 100 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">symptoms of inflammation of the pancreas (pancreatitis) such as severe and persistent stomach pain, with or without nausea and vomiting (may affect up to 1 in 100 people).</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">shortness of breath or cough (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">flu-like symptoms followed by a painful red or purplish rash that spreads and blisters including extensive detachment of the skin (may affect up to 1 in 100 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">a change in feeling or sensitivity, especially in the skin, numbness, tingling, discomfort, a burning sensation, weakness, or pain in the hands or feet (neuropathy; may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">a feeling of weakness (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">constipation (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">diarrhoea, vomiting (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">chills or shivering (may affect up to 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">feeling tired, frequent urination, increased thirst, increased appetite with unintended weight loss, and irritability (these may be signs of hyperglycaemia, which may affect up to 1 in 10 people)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">unusual bleeding or bruising under the skin, longer than usual bleeding after your blood has been drawn, or bleeding from your gums (these may be signs of thrombocyopenia which may affect up to 1 in 10 people)</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">headaches, experience dizziness, look pale (these may be signs of anaemia, which may affect more than 1 in 10 people)</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">You may experience the following side effects:</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">The following side effects have been reported with Adcetris alone:</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="margin-left:.25in;page-break-after:avoid"><b><span lang="EN-GB">Very common side effects</span></b><span lang="EN-GB"> (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of white blood cells</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">upper respiratory tract infection</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decrease in weight</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">infection</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">nausea</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">abdominal pain</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">itching</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">muscle pain</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">joint pain or painful, swollen joints</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:.25in;page-break-after:avoid"><b><span lang="EN-GB">Common side effects</span></b><span lang="EN-GB"> (may affect up to 1 in 10 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">pneumonia</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">sore, creamy-yellow, raised patches in the mouth (thrush)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of blood platelets</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">dizziness</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">blisters which may crust or scab</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">increased level of blood sugar</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">increased liver enzyme levels </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">unusual hair loss or thinning</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:21.3pt;page-break-after:avoid"><b><span lang="EN-GB">Uncommon side effects</span></b><span lang="EN-GB"> (may affect up to 1 in 100 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">Tumour lysis syndrome – a potentially-life threatening condition in which you may experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances. </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">new or recurring cytomegalovirus (CMV) infection</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">an infection in the blood (sepsis) and/or septic shock (a life-threatening form of sepsis)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">Stevens-Johnson syndrome and toxic epidermal necrolysis - a rare, serious disorder in which you may experience flu-like symptoms followed by a painful red or purplish rash that spreads and blisters including extensive detachment of the skin </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of white blood cells with a fever</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">damage to the nerves and nerve coverings (demyelinating polyneuropathy)</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">The following side effects have been reported with Adcetris in combination with chemotherapy medicines:</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:.25in;page-break-after:avoid"><b><span lang="EN-GB">Very common side effects</span></b><span lang="EN-GB"> (may affect more than 1 in 10 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of white blood cells</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of blood platelets</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased level of white blood cells with a fever</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">upper respiratory tract infection</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decrease in weight</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">infection</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">nausea</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">abdominal pain</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">unusual hair loss or thinning</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">muscle pain</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">joint pain or painful, swollen joints</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">dizziness</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">decreased appetite</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">not being able to sleep</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">bone pain</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">blisters which may crust or scab</span></p><p class="MsoNormal" style="margin-left:28.35pt"></p><p class="MsoNormal" style="margin-left:.25in;page-break-after:avoid"><b><span lang="EN-GB">Common side effects</span></b><span lang="EN-GB"> (may affect up to 1 in 10 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">an infection in the blood (sepsis) and/or septic shock (a life-threatening form of sepsis); pneumonia</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">sore or inflammation in the mouth</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">sore, creamy-yellow, raised patches in the mouth (thrush)</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">itching</span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">increased level of blood sugar</span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">increased liver enzyme levels</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:21.3pt;page-break-after:avoid"><b><span lang="EN-GB">Uncommon side effects</span></b><span lang="EN-GB"> (may affect up to 1 in 100 people)</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">Tumour lysis syndrome – a potentially-life threatening condition in which you may experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">Stevens‑Johnson syndrome - a rare, serious disorder in which you may experience flu‑like symptoms followed by a painful red or purplish rash that spreads and blisters including extensive detachment of the skin </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">new or recurring cytomegalovirus (CMV) infection</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">If you are an older patient (≥ 65 years of age) you may experience serious adverse events more frequently. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Reporting of side effects</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet.</span><span lang="EN-GB"> You can also report side effects directly via <span style="background:silver">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="background:silver">Appendix V</span></a><a name="_Hlt351112648"></a><a name="_Hlt351112647"></a></span><span lang="EN-GB">. By reporting side effects you can help provide more information on the safety of this medicine.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">5.       How to store Adcetris </span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Keep this medicine out of the sight and reach of children.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not use this medicine after the expiry date which is stated on the vial label and the carton after EXP. The expiry date refers to the last day of that month. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><b><span lang="EN-GB">Unopened vial:</span></b><span lang="EN-GB"> Store in a refrigerator (2 °C‑8 °C). Do not freeze.</span></p><p class="MsoNormal"><span lang="EN-GB">Keep the vial in the original carton in order to protect from light. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><b><span lang="EN-GB">Reconstituted/diluted solution:</span></b><span lang="EN-GB">Use immediately or </span><span lang="EN-GB">store in a refrigerator (2 </span><span lang="EN-GB" style="font-family:Symbol">°</span><span lang="EN-GB">C‑8 °C) and use within 24 hours.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not use this medicine if you notice any particulate matter or discolouration prior to administration. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not throw away any medicines via wastewater or household waste. The doctor or nurse will dispose of this medicine. These measures will help protect the environment. </span></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoHeading7" style="page-break-after:avoid"><span lang="EN-GB">6.       Contents of the pack and other information</span></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">What Adcetris contains</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">The active substance is brentuximab vedotin. Each vial contains 50 mg of brentuximab vedotin. After reconstitution each mL of solution contains </span><span lang="EN-GB">5 mg of Adcetris. </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style='font-family:"Times",serif'>-</span><span lang="EN-GB">The other ingredients are citric acid monohydrate, sodium citrate dihydrate, α,α‑trehalose dihydrate, and polysorbate 80 See section 2 for further information about sodium. </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">What Adcetris looks like and contents of the pack</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is a white to off-white cake or powder for concentrate for solution for infusion provided in a glass vial. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Each pack of Adcetris consists of one vial. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><a name="_Hlk19873870"><b><span lang="EN-GB">Marketing Authorisation Holder</span></b></a></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Takeda Pharma A/S</span></p><p class="MsoNormal"><span lang="EN-GB">Dybendal Alle 10</span></p><p class="MsoNormal"><span lang="EN-GB">2630 Taastrup</span></p><p class="MsoNormal"><span lang="EN-GB">Denmark </span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Manufacturer</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="background:silver">Takeda Austria GmbH</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="background:silver">St. Peter‑Straβe 25</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="PT" style="background:silver">A‑4020 Linz</span></p><p class="MsoNormal"><span lang="PT" style="background:silver">Austria</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="PT">Delpharm Novara S.r.l.</span></p><p class="MsoNormal"><span lang="IT">Via Crosa, 86</span></p><p class="MsoNormal"><span lang="EN-GB">28065 Cerano (NO) </span></p><p class="MsoNormal"><span lang="EN-GB">Italy</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</span></p><p class="MsoNormal"></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse"> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="DE" style="color:windowtext">België/Belgique/Belgien</span></b></p> <p class="MsoNormal"><span lang="DE" style="color:windowtext">Takeda Belgium</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="DE" style="color:windowtext">Tél/Tel: +32 2 464 06 11</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">takeda-belgium@takeda.com</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="FI" style="color:windowtext">Lietuva</span></b></p> <p class="MsoNormal"><span lang="FI" style="color:windowtext">Takeda, UAB</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="FI" style="color:windowtext">Tel: +370 521 09 070</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="FI" style="color:windowtext">lt-info@takeda.com</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:windowtext">България</span></b></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Такеда   България</span></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Тел.: + 359 2 958 27 36</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal"><b><span lang="DE" style="color:windowtext">Luxembourg</span></b><b><span lang="DE" style="color:windowtext">/Luxemburg</span></b></p> <p class="MsoNormal"><span lang="DE" style="color:windowtext">Takeda Belgium</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="DE" style="color:windowtext">Tél:/Tel: +32 2 464 06 11</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">takeda-belgium@takeda.com<span class="MsoHyperlink"></span></span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Česká republika</span></b></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Takeda   Pharmaceuticals </span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Czech Republic   s.r.o.</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">Tel: + 420 23<span style="letter-spacing:1.9pt">4</span>72<span style="letter-spacing:1.9pt">2</span>722 </span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Magyarország</span></b></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Takeda Pharma Kft.</span></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Tel.: +361 2707030</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Danmark</span></b></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">Takeda Pharma A/S</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">Tlf: +45 46 77 11 11</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="FI" style="color:windowtext">Malta</span></b></p> <p class="MsoPlainText"><span lang="FI" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda   Italia S.p.A.</span></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Tel: +39 06 502601</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;   page-break-after:avoid"><b><span lang="DE" style="color:windowtext">Deutschland</span></b></p> <p class="MsoPlainText"><span lang="DE" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda   GmbH</span></p> <p class="MsoPlainText"><span lang="DE" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:   +49 (0) 800 825 3325</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="DE" style="color:windowtext">medinfo@takeda.de</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="SV" style="color:windowtext">Nederland</span></b></p> <p class="MsoPlainText"><span lang="SV" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda   Nederland bv</span></p> <p class="MsoPlainText"><span lang="SV" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tel:   +31 23 56 68 777</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="SV" style="color:windowtext">nl.medical.info@takeda.com</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="PT-BR" style="color:windowtext">Eesti</span></b></p> <p class="MsoNormal"><span lang="PT-BR" style="color:windowtext">Takeda Pharma AS</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="PT-BR" style="color:windowtext">Tel: +372 6177 669</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="NO-NYN" style="color:windowtext">Norge</span></b></p> <p class="MsoNormal"><span lang="NO-NYN" style="color:windowtext">Takeda AS</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="NO-NYN" style="color:windowtext">Tlf: +47 6676 3030</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="NO-NYN" style="color:windowtext">infonorge@takeda.com</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Ελλάδα</span></b></p> <p class="MsoNormal"><span lang="NO-NYN" style="color:windowtext">TAKEDA </span><span lang="EN-GB" style="color:windowtext">ΕΛΛΑΣ</span><span lang="EN-GB" style="color:windowtext">Α</span><span lang="NO-NYN" style="color:windowtext">.</span><span lang="EN-GB" style="color:windowtext">Ε</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="NO-NYN" style="color:windowtext">T</span><span lang="EL" style="color:windowtext">ηλ</span><span lang="EN-GB" style="color:windowtext">: +30 210 6387800</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="DE" style="color:windowtext">gr.info@takeda.com</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="DE" style="color:windowtext">Österreich</span></b></p> <p class="Default"><span lang="DE" style="font-size:11.0pt;color:windowtext">Takeda   Pharma Ges.m.b.H. </span></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Tel: +43 (0) 800 20 80 50 </span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="ES" style="color:windowtext">España</span></b></p> <p class="MsoNormal"><span lang="ES" style="color:windowtext">Takeda   Farmacéutica España S.A</span></p> <p class="MsoPlainText"><span lang="EN-GB" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Tel: +34 </span><span style='font-size:11.0pt;   font-family:"Times New Roman",serif'>917 90 42 22</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">spain@takeda.com</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="PL" style="color:windowtext">Polska</span></b></p> <p class="MsoNormal"><span lang="PL" style="color:windowtext">Takeda Pharma sp. z   o.o.</span></p> <p class="MsoNormal"><span lang="FR" style="color:windowtext">Tel.: + 48 22 608   13 00</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="FR" style="color:windowtext">France</span></b></p> <p class="MsoNormal"><span lang="FR" style="color:windowtext">Takeda France </span></p> <p class="MsoNormal"><span lang="EN-GB">Tél</span><span lang="EN-GB">:</span><span lang="FR" style="color:windowtext"> +33 1 46 25 16 16</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="PT-BR" style="color:windowtext">Portugal</span></b></p> <p class="MsoPlainText"><span lang="PT-BR" style='font-size:11.0pt;font-family:   "Times New Roman",serif'>Takeda Farmacêuticos Portugal, Lda.</span></p> <p class="MsoNormal"><span lang="FR" style="color:windowtext">Tel: + 351 21 120   1457</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span style="color:windowtext">Hrvats</span></b><b><span lang="EN-GB" style="color:windowtext">ka</span></b></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">Takeda Pharmaceuticals Croatia d.o.o.</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">Tel: +385 1 377 88 96</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal"><b><span lang="EN-GB" style="color:windowtext">România   </span></b></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Takeda   Pharmaceuticals SRL</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">Tel: +40 21 335 03 91</span></p> <p class="MsoNormal" style="text-indent:28.35pt"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Ireland</span></b></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Takeda Products   Ireland Limited</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Tel: +44 (0)1628   537 900</span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="NO-NYN" style="color:windowtext">Slovenija</span></b></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="NO-NYN" style="color:windowtext">Takeda GmbH, Podružnica Slovenija</span></p> <p class="MsoNormal"><span lang="NO-NYN" style="color:windowtext">Tel: + 386 (0)   59 082 480</span></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Ísland</span></b></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Vistor hf. </span></p> <p class="MsoNormal"><span lang="EN-GB">Sími:</span><span lang="EN-GB" style="color:windowtext"> +354 535 7000</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">vistor@vistor.is</span></p> <p class="MsoNormal" style="text-indent:28.35pt"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Slovenská republika</span></b></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Takeda   Pharmaceuticals Slovakia s.r.o.</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Tel: +421 (2) 20   602 600</span></p> <p class="MsoNormal"></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoPlainText" style="page-break-after:avoid"><b><span lang="ES" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Italia </span></b></p> <p class="MsoPlainText"><span lang="ES" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Takeda   Italia S.p.A.</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">Tel: +39 06   502601</span></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="SV" style="color:windowtext">Suomi/Finland</span></b></p> <p class="MsoNormal"><span lang="SV" style="color:windowtext">Takeda Oy</span></p> <p class="MsoNormal"><span lang="SV">Puh/Tel:</span><span lang="SV" style="color:windowtext"> +358 20 746 5000</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:windowtext">infoposti@takeda.com</span></p> <p class="MsoNormal"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="EN-GB" style="color:windowtext">Κύπρος</span></b></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">A. POTAMITIS MEDICARE LTD</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:windowtext">Tηλ: +357 22583333</span></p> <p class="MsoNormal"><span lang="LV" style="color:windowtext">info@potamitismedicare.com</span></p> <p class="MsoNormal"><span lang="LV" style="color:windowtext"><a href="mailto:info@potamitismedicare.com"></a></span></p> <p class="MsoNormal"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="SV" style="color:windowtext">Sverige</span></b></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="SV" style="color:windowtext">Takeda Pharma AB</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="SV" style="color:windowtext">Tel: +46 8 731 28 00</span></p> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:windowtext">infosweden@takeda.com</span></p> <p class="MsoNormal" style="text-indent:28.35pt"></p> </td> </tr> <tr> <td style="width:232.15pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;   page-break-after:avoid"><b><span lang="FI" style="color:windowtext">Latvija</span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="FI" style="color:windowtext">Takeda Latvia SIA</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="FI" style="color:windowtext">Tel: +371 67840082</span></p> <p class="MsoNormal" style="text-indent:28.35pt;page-break-after:avoid"></p> </td> <td style="width:232.2pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="310"> <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;   page-break-after:avoid"><b><span lang="EN-GB" style="color:windowtext">United   Kingdom</span></b></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">Takeda UK Ltd</span></p> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:windowtext">Tel: +44 (0)1628 537 900</span></p> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">This leaflet was last revised in</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Detailed information on this medicine is available on the European Medicines Agency website: </span><u><span lang="EN-GB" style="color:blue">http://www.ema.europa.eu/</span></u></p><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">----------------------------------------------------------------------------------------------------------------------</span></p><p class="MsoNormal"><span lang="EN-GB">The following information is intended for healthcare professionals only:</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Traceability</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Disposal </span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Adcetris is for single use only. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Any unused product or waste material should be disposed of in accordance with local requirements.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Instructions for reconstitution </span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">Each single use vial must be reconstituted with 10.5 mL of water for injections to a final concentration of 5 mg/mL. Each vial contains a 10% overfill giving 55 mg of Adcetris per vial and a total reconstituted volume of 11 mL.</span></p><p class="MsoListParagraphCxSpFirst" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">1.</span><span lang="EN-GB">Direct the stream toward the wall of the vial and not directly at the cake or powder. </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB">2.</span><span lang="EN-GB">Gently swirl the vial to aid dissolution. DO NOT SHAKE. </span></p><p class="MsoListParagraphCxSpMiddle" style="margin-left:28.35pt;text-indent: -28.35pt"><span lang="EN-GB">3.</span><span lang="EN-GB">The reconstituted solution in the vial is a clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p><p class="MsoListParagraphCxSpLast" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB">4.</span><span lang="EN-GB">The reconstituted solution should be inspected visually for any foreign particulate matter and/or discolouration. In the event of either being observed, discard the medicinal product.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Preparation of Infusion Solution</span></b></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal"><span lang="EN-GB">The appropriate amount of reconstituted Adcetris must be withdrawn from the vial(s) and added to an infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection in order to achieve a final concentration of 0.4‑1.2 mg/mL Adcetris. The recommended diluent volume is 150 mL. The already reconstituted Adcetris can also be diluted into 5% dextrose for injection or Lactated Ringer's for injection. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Gently invert the bag to mix the solution containing Adcetris. DO NOT SHAKE. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Any portion left in the vial, after withdrawal of the volume to be diluted, must be disposed of in accordance with local requirements. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Do not add other medicinal products to the prepared Adcetris infusion solution or intravenous infusion set. The infusion line should be flushed following administration with sodium chloride 9 mg/mL (0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's for injection. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Following dilution, infuse the Adcetris solution immediately at the recommended infusion rate. </span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Total storage time of the solution from reconstitution to infusion should not exceed 24 hours.</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>